Document:

EX-10.4

 Exhibit 10.4 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

Execution Copy 
 ASSET PURCHASE AGREEMENT 
 This Asset Purchase Agreement
(“Agreement”) is entered into by and between Ampio Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 5445 DTC Parkway, Suite 925, Greenwood Village, Colorado 80111, USA
(“Ampio”), and Valeant International (Barbados) SRL (formerly Biovail Laboratories International SRL), a society with restricted liability established under the laws of Barbados, with its principal place of business at Welches,
Christ Church, Barbados, West Indies (“VIB”), as of December 2, 2011 (the “Effective Date”). 
 RECITALS 
 WHEREAS, DMI BioSciences, Inc. (“DMI”), a
wholly-owned subsidiary of Ampio, and VIB were parties to a certain License and Development Agreement dated August 7, 2007, as amended (the “DMI-VIB License Agreement”) concerning, in
part, the development and commercialization of tramadol for the treatment of premature ejaculation; and 
 WHEREAS, VIB has
terminated the DMI-VIB License Agreement with DMI; and 
 WHEREAS, VIB is a party to a
certain NDA Assignment and License Agreement by and between VIB and Ethypharm, a societe anonyme organized under the laws of France with its principal place of business at 194 Bureaux de la Colline, 92213 Saint-Cloud, France
(“Ethypharm”), dated February 6, 2009 (the “NDA Agreement”); and 
 WHEREAS, VIB has
certain rights in and to the Tramadol Product (as defined below); and 
 WHEREAS, Ampio wishes to have the NDA Agreement
assigned to it and wishes to acquire VIB’s rights to the Tramadol Product and VIB is willing to assign the NDA Agreement to Ampio and sell to Ampio its rights to the Tramadol Product, all on the terms set forth herein. 

NOW, THEREFORE, in consideration of the foregoing premises and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties agree as follows. 

 ARTICLE 1 
 DEFINITIONS AND INTERPRETATION 
 1.1 Definitions. Capitalized terms and phrases used
herein and not otherwise defined or modified hereinbelow shall have the respective meanings ascribed thereto in the Agreement. 

“Active Ingredient” means the chemical compound known as (i) tramadol (base), (ii) any salt of tramadol, (iii) any
metabolites, isomers, enantiomers, polymorphs or pro-drugs of tramadol or of any salt of tramadol, and (iv) any compounds obtained by forming or breaking a
non-covalent bond with or of any of (i), (ii) or (iii) if such compounds retain the activity of tramadol. 
 “Additional Consideration” has the meaning set forth in Section 3.2 herein. 

“Affiliate” of any Person means, at the time such determination is being made, any other Person Controlling, Controlled by or under
common Control with such first Person, in each case, whether directly or indirectly. For the purposes of this definition, a Person will be deemed to “Control” another Person if such first Person has (a) direct or indirect ownership of
more than fifty percent (50%) of the equity (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) having the power to vote on or direct the affairs of such other Person, or
(b) the power, directly or indirectly, to direct or cause the direction of the policies and management of the other Person, whether by the ownership of stock, by contract, or otherwise. 
 “Agreement” has the meaning set forth in the first paragraph above. 

“Ampio” has the meaning set forth in the first paragraph above. 
 “Ampio Closing Certificate” has the meaning set forth in Section 4.3.2 herein. 
 “Ampio Closing Deliverables” has the meaning set forth in Section 4.3 herein. 
 “Ampio Indemnified Parties” has the meaning set forth in Section 8.2 herein. 

“Ampio Product” means the oral rapid dissolve tablet formulation of the Active Ingredient, whether as the only active pharmaceutical
ingredient or in combination with other active pharmaceutical ingredients, with an indication outside of the field of pain. 

“Applicable Law” means applicable law (including common law and civil law), statutes, by-laws,
rules, regulations, Orders, ordinances, protocols, codes, guidelines, treaties, policies, notices, directions, decrees, judgments, awards or requirements, in each case of any Governmental Entity. 

“Assumed Liabilities” has the meaning set forth in Section 2.3 herein. 
 “Assumption Agreement” means an assumption agreement to be entered into by Ampio and VIB at Closing, substantially in the form of Exhibit A. 

“Bill of Sale” means a bill of sale and assignment to be entered into by Ampio and VIB at Closing, substantially in the form of
Exhibit B. 

  
 2 

 “Business Day” means any day other than a Saturday, Sunday or other day on which banks in
the State of Colorado or in Barbados are permitted or required to close by any Applicable Law. 
 “Calendar Quarter” means the
three-month period commencing January 1, April 1, July 1 or October 1. 
 “Closing” has the
meaning set forth in Section 4.1 herein. 
 “Closing Date” has the meaning set forth in Section 4.1 herein.

 “Closing Time” has the meaning set forth in Section 4.1 herein. 

“Contract Assignment and Assumption Agreement” means the Contract Assignment and Assumption Agreement to be entered into by Ampio and
VIB at Closing, with respect to the assignment by VIB, and assumption by Ampio, of the NDA Agreement, substantially in the form of Exhibit C. 
 “Control” or “Controlled” means that a right is owned, licensed, or otherwise possessed by a Party with the right to license or
sub-license without consent. 
 “DMI” has the meaning set forth in the Recitals above.

 “DMI-VIB License Agreement” has the meaning set forth in the Recitals above.

 “Effective Date” has the meaning set forth in the first paragraph above. 

“Ethypharm” has the meaning set forth in the Recitals. 
 “Ethypharm Consent” has the meaning set forth in Section 4.4.3 herein. 

“Excluded Assets” has the meaning set forth in Section 2.2 herein. 
 “Governmental Entity” means governments, regulatory authorities, governmental departments, agencies, agents, commissions, bureaus, officials, ministers, Crown corporations, courts,
bodies, boards, tribunals or dispute settlement panels or other law, rule or regulation-making organizations or entities. 

“Indemnified Party” has the meaning set forth in Section 8.4.1 herein. 
 “Indemnifying Party” has the meaning set forth in Section 8.4.1 herein. 

“Initial Consideration” has the meaning set forth in Section 3.1 herein. 
 “Know-How” means scientific, medical, technical, clinical, regulatory, manufacturing, trade and marketing information, data and materials, and trade secrets. 

“Liabilities” means any and all debts, liabilities and obligations, whether accrued or fixed, absolute or contingent, matured or
unmatured, or determined or determinable, including those arising under any law, action or governmental order and those arising under any contract, agreement, arrangement, commitment or undertaking, or otherwise. 

  
 3 

 “Losses” means, collectively, any and all damages, losses, taxes, Liabilities, claims,
judgments, penalties, costs and expenses (including reasonable attorneys’ fees and litigation expenses). 
 “NDA
Agreement” has the meaning set forth in the Recitals above. 
 “Net Sales” means the amount of gross sales of Ampio
Products in the Territory for a specified period sold by Ampio, its Affiliates or licensees or subcontractors to Third Parties less the following items as applicable to the Ampio Products, all in accordance with standard allocation procedures,
allowance methodologies and accounting methods consistently applied in accordance with U.S. Generally Accepted Accounting Principles (“US GAAP”): 
  

	 	(i)	credits or allowances actually granted for damaged products, returns or rejections of product, price adjustments and billing errors; 

 

	 	(ii)	governmental and other rebates (or equivalents thereof) granted to managed health care organizations, pharmacy benefit managers (or equivalents thereof), federal,
provincial, local and other governments, their agencies and purchasers, and reimbursers or to trade customers; 

  

	 	(iii)	normal and customary trade, cash and quantity discounts, allowances and credits; 

 

	 	(iv)	transportation costs, including insurance, for outbound freight related to delivery of the product to the extent included in the gross amount invoiced; and

  

	 	(v)	sales taxes, value added taxes and other taxes directly applied to the sale of the product to the extent included in the gross amount invoiced.

 In no event shall any particular amount, identified above, be deducted more than once in calculating Net Sales (i.e., no
“double counting” of reductions). Sales of Ampio Product between Ampio and its Affiliates or licensees or subcontractors for resale shall be excluded from the computation of Net Sales, but the subsequent resale of such Ampio Product to a
Third Party shall be included within the computation of Net Sales. 
 “Party” means either VIB or Ampio and “Parties”
means both VIB and Ampio. 
 “Person” means any individual, sole proprietorship, partnership, firm, entity, unincorporated
association, unincorporated syndicate, unincorporated organization, trust, body corporate, Governmental Entity, and where the context requires any of the foregoing when they are acting as trustee, executor, administrator or other legal
representative. 
 “Product Liability Claims” means any product liability claims asserted or filed by Third Parties (without
regard to their merit or lack thereof), seeking damages or equitable relief of any kind, relating to personal injury, wrongful death, medical expenses, an alleged need for medical monitoring, consumer fraud or other alleged economic losses,
allegedly caused by the Ampio Product, and including claims by or on behalf of users of the Ampio Product (including spouses, family members and personal representatives of such users) relating to the use, sale, distribution or purchase of the Ampio
Product sold by or on behalf of Ampio or its Affiliates, distributors or licensees. 

  
 4 

 “Purchased Assets” means all of VIB’s rights, title and interest in (i) the NDA
Agreement, (ii) the Tramadol Know-How, and (iii) the Samples. 
 “Retained Liabilities” has the meaning set forth in
Section 2.4 herein. 
 “Samples” means the tablets of [***] of the Tramadol Product used by VIB or its Affiliates in those
[***] studies known to VIB as [***], in the amounts set out in and as otherwise described in the disposition reports attached as Schedule A to the Technology Transfer Plan. 
 “Technology Transfer Plan” means the technology transfer plan attached hereto as Exhibit E. 
 “Territory” means worldwide. 
 “Third Party” means any Person
other than VIB or Ampio or their respective Affiliates. 
 “Third Party Claim” has the meaning set forth in Section 8.4.2
herein. 
 “Tramadol Know-How” means the Know-How Controlled by VIB as of the Closing
Date (for purposes of clarity, including Affiliates of VIB) relating to the Tramadol Product, which Know-How is set out on the Technology Transfer Plan (including Tramadol
Know-How identified as “essential” and “non-essential”), and all of VIB’s rights thereto. 
 “Tramadol Product” means the oral rapid dissolve tablet formulation of the Active Ingredient [***] developed by VIB for use in the indication of premature ejaculation. 

“Transaction Documents” means: (i) the Assumption Agreement; (ii) the Contract Assignment and Assumption Agreement;
(iii) the Bill of Sale; and (iv) other documents contemplated hereby and thereby. 
 “US GAAP” has the meaning set
forth in the definition of “Net Sales” in Section 1.1 herein. 
 “VIB” has the meaning set forth in the first
paragraph above. 
 “VIB Closing Certificate” has the meaning set forth in Section 4.4.2 herein. 

“VIB Closing Deliverables” has the meaning set forth in Section 4.4 herein. 

“VIB Indemnified Parties” has the meaning set forth in Section 8.3 herein. 

 
  

	*	Confidential Information, indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission. 

  
 5 

	1.2	Interpretation. 

  

	1.2.1	Including. When used in this Agreement, the words “include”, “includes” and “including” shall be deemed to be followed by the words
“without limitation.” 

  

	1.2.2	Number. Any terms defined in the singular shall have a comparable meaning when used in the plural, and vice-versa. 

 

	1.2.3	Section References, Etc. All references to any introductory paragraph, recitals, Articles, Sections and Exhibits shall be deemed references to the introductory
paragraph, recitals, Articles, Sections and Exhibits to this Agreement. 

  

	1.2.4	Gender. A reference to one gender shall include any other gender. 

  

	1.2.5	Headings. Headings of Articles and Sections are inserted for convenience of reference only and do not affect the construction or interpretation of this
Agreement. 

  

	1.2.6	No Strict Construction. The language used in this Agreement is the language chosen by the Parties to express their mutual intent, and no rule of strict
construction shall be applied against any Party. 

  

	1.2.7	Statutes. A reference to a statute includes all regulations and rules made pursuant to such statute and, unless otherwise specified, the provisions of any
statute, regulation or rule which amends, supplements or supersedes any such statute, regulation or rule. 

  

	1.2.8	Time Periods. Unless otherwise specified, time periods within or following which any payment is to be made or act is to be done shall be calculated by excluding
the day on which the period commences and including the day on which the period ends and by extending the period to the next Business Day following if the last day of the period is not a Business Day. 

1.3     Currency. All currency amounts referred to in this Agreement are in United States Dollars unless otherwise specified.

 ARTICLE 2 
 PURCHASE AND SALE 
 2.1     Sale of the Purchased Assets.
Subject to the provisions of this Agreement, VIB shall, on the Closing Date, sell, assign, convey, transfer and deliver to Ampio, and Ampio shall purchase, acquire and accept, all right, title and interest of VIB in the Purchased Assets. 

2.2     Excluded Assets. Purchaser and Seller expressly agree and acknowledge that the Purchased Assets shall not include any
other asset, property or right of Seller not referenced in the definition of “Purchased Assets” set forth in Section 1.1 (collectively, the “Excluded Assets”). 

  
 6 

 2.3     Assumption of Certain Liabilities and Obligations. As of the Closing
Date, Ampio shall assume control of, and responsibility for, all costs, obligations and Liabilities arising from or related to the Purchased Assets that relate to the period on or following the Closing (“Assumed Liabilities”). For
greater certainty, the Assumed Liabilities shall include all of VIB’s liabilities and obligations under the NDA Agreement and Ampio agrees to be responsible for the full performance and discharge of all of VIB’s obligations, duties and
responsibilities under the NDA Agreement, in each case arising from and after the Closing Date. 
 2.4     Retained
Liabilities. VIB shall retain and shall be fully responsible for all costs, obligations and Liabilities arising from or related to (i) the Purchased Assets that relate to the period prior to the Closing, (ii) the Samples and Tramadol Know-How until such time they are transferred to Ampio, and (iii) the Excluded Assets (collectively, the “Retained Liabilities”). For greater certainty, the Retained Liabilities shall include
any Liabilities and obligations of VIB under the NDA Agreement that relate to the period prior to the Closing Date, regardless of when such Liabilities arise. 
 2.5     Assignment and Assumption of the NDA Agreement. As of the Closing Date and subject to receipt of the Ethypharm consent, VIB shall assign and Ampio shall assume the NDA
Agreement; provided however that Ampio shall assume only those Liabilities and obligations under the NDA Agreement that relate to the period commencing on the Closing Date. The Parties agree and acknowledge that the assignment of the NDA Agreement
requires the consent of Ethypharm and that the receipt of such Ethypharm Consent is a condition of Closing that must be waived by both Parties for the Closing to occur if such Ethypharm Consent is not received from Ethypharm. Ampio shall assist and
cooperate with VIB in connection with the obtaining of the Ethypharm Consent. The Parties acknowledge and agree that neither Party shall be required to pay money to Ethypharm or any other Person, commence litigation or offer or grant any
accommodation (financial or otherwise) to Ethypharm or any other Person in connection with such efforts. 
 2.6    
Samples. The Samples, which form part of the Purchased Assets, shall be sold and transferred to Ampio on an “as is, where is” basis and VIB shall provide no representations or warranties with respect to the Samples, including as to
fitness for use, except as specifically set forth herein. 
 ARTICLE 3 

PURCHASE PRICE 

3.1     Initial Consideration. As consideration, in part, for the Purchased Assets, Ampio shall pay to VIB, in the aggregate,
Two Million US Dollars (US$2,000,000) (the “Initial Consideration”), which amount shall be non-refundable and non-creditable against other payments due
under this Agreement and which amount shall be payable within five (5) calendar days of the date on which VIB has completed the transfer to Ampio of the Samples and the Tramadol Know-How identified as
“essential” in the Technology Transfer Plan, in accordance with the terms of this Agreement. 

  
 7 

 3.2     Additional Consideration. As additional consideration for the Purchased
Assets, Ampio shall pay to VIB additional amounts equal to [***] of the aggregate annual Net Sales of any Ampio Product (the “Additional Consideration”). The Additional Consideration shall be paid on a quarterly basis, within thirty
(30) days of the end of the applicable Calendar Quarter. Within thirty (30) days after the end of each Calendar Quarter during which there are Net Sales, Ampio shall deliver a report to VIB specifying the Net Sales of the Ampio Product for
the applicable Calendar Quarter. Together with the delivery of such report, Ampio shall pay to VIB the Additional Consideration applicable to such Calendar Quarter. 
 3.3     Transfer Taxes and Withholding. Despite any other provision contained in this Agreement to the contrary, in respect of the purchase and sale of the Purchased Assets
under this Agreement, each Party shall pay direct to the appropriate Governmental Entity all sales and transfer taxes, registration charges and transfer fees payable by it. All taxes levied on account of the payments accruing to VIB under this
Agreement shall be paid by VIB for its own account, including taxes levied thereon as income to VIB. If Applicable Law requires that taxes be deducted and withheld from a payment, the remitting Party shall (i) deduct those taxes from the
payment; (ii) pay the taxes to the proper taxing authority; (iii) send evidence of the obligation together with proof of payment to the other Party within sixty (60) days following that payment; and (iv) shall provide such
assistance as the other Party may reasonably require in obtaining any refund of such amounts to which the other Party may be entitled, to the extent that such assistance does not cause the remitting Party to incur any liability in respect of the
taxes asserted to be due. 
 3.4     Mode of Payment. Each Party shall pay all amounts due under this Agreement in US
funds by bank wire transfer in immediately available funds to such bank as the other may direct in writing from time to time. 

3.5     Late Payments. In the event that any uncontested payment due under this Agreement is not made when due, the payment
shall accrue interest from the date due at a rate per annum equal to four per cent (4%) above the U.S. Prime Rate (as set forth in the Wall Street Journal, Eastern Edition) for the date on which payment was due, calculated daily on the basis of
a 365-day year, or similar reputable data source; provided that, in no event shall such rate exceed the maximum interest rate allowable under Applicable Law. 

3.6     Records. Ampio shall keep, and require its Affiliates, licensees and distributors to keep, a true and accurate account
of the Ampio Product distributed or sold in the Territory. Such books and records shall be kept for such period of time required by Applicable Law, but no less than at least three (3) years following the end of the Calendar Quarter to which
they pertain. 
  

	3.7	Audit Rights. 

  

	3.7.1	VIB shall have the right, through a certified public accountant or like person reasonably acceptable to Ampio, upon execution of a reasonable confidentiality agreement,
to examine the records of Ampio, or its Affiliates or, if Ampio has the right, its licensees or 

  

 

	*	Confidential Information, indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission. 

  
 8 

 
subcontractors, during regular business hours upon reasonable notice and for one (1) calendar year after its termination; provided, however, that: (a) such examination shall not take
place more often than once a calendar year and shall not cover such records for more than the preceding calendar year, and (b) such accountant shall report to VIB only as to the accuracy of the reports or payments of Additional Consideration
provided or made by Ampio under this Agreement. The accountant shall send a copy of the report to Ampio at the same time it is sent to VIB. 

3.7.2     In negotiating any agreements or contracts with its licensees and subcontractors of Ampio Products hereunder, Ampio shall
use its commercially reasonable efforts to include a provision permitting VIB to conduct an audit of each such licensee or subcontractor in the manner described in Section 3.7.1 above. If Ampio is unable to successfully negotiate the inclusion
of such a provision, then Ampio agrees that, on request from VIB, it will conduct an audit, in accordance with the terms of Ampio’s contract or agreement with such licensee or subcontractor, of such licensee’s or subcontractor’s books
and records to the extent they relate to the sale of an Ampio Product and shall provide the results of such audit to VIB, to the extent permitted under the terms of any such contract or agreement with such licensee or subcontractor. 

3.7.3     Inspections conducted under this Section 3.7 shall be at the expense of VIB, unless a variation or error producing an
underpayment in amounts payable by Ampio to VIB as Additional Consideration exceeding an amount equal to five per cent (5%) of the amount paid for a period covered by the inspection is established, in which case all reasonable costs relating to
the inspection for such period and any unpaid amounts that are discovered shall be paid by Ampio. 
 ARTICLE 4 

THE CLOSING 
 4.1     Closing Date. Upon the terms and subject to the conditions of this Agreement, the closing of the Agreement and the transfer of the Purchased Assets and rights pursuant
to this Agreement (the “Closing”) shall be held at 8:00 a.m. (ET) or such other time as the Parties may mutually agree in writing (the “Closing Time”) on the second (2nd) Business Day immediately following the receipt of the
Ethypharm Consent executed on behalf of Ethypharm, or such other date as the Parties may mutually agree in writing (the “Closing Date”). Notwithstanding the foregoing, the Closing shall be deemed to occur at 12:01 a.m. ET on the
Closing Date. 
 4.2     Place of Closing. The Closing shall take place at the offices of VIB located at Welches,
Christ Church, Barbados, or at such other place or method as may be agreed upon by the Parties. 
 4.3     Closing
Deliverables by Ampio. At the Closing, subject to the terms and conditions set forth herein, Ampio shall do or otherwise cause each of the following to occur (collectively, the “Ampio Closing Deliverables”): 

 

	4.3.1	Deliver to VIB duly executed copies of the Transaction Documents to which it is a party; and 

  
 9 

	4.3.2	Deliver to VIB a certificate executed by a duly authorized officer of Ampio dated the Closing Date, certifying that the representations and warranties of Ampio set
forth in this Agreement and the Transaction Documents are true and correct in all material respects as of the Closing Date, except to the extent such representations and warranties relate to an earlier date (in which case such representations and
warranties will be true and correct as of such earlier date) (the “Ampio Closing Certificate”). 

4.4     Closing Deliverables by VIB. At the Closing, subject to the terms and conditions set forth herein, VIB shall do or
otherwise cause each of the following to occur (collectively, the “VIB Closing Deliverables”): 
  

	4.4.1	Deliver to Ampio duly executed copies of the Transaction Documents to which it is a party; 

 

	4.4.2	Deliver to Ampio a certificate executed by a duly authorized officer of VIB dated the Closing Date, certifying that the representations and warranties of VIB set forth
in this Agreement and the Transaction Documents are true and correct in all material respects as of the Closing Date, except to the extent such representations and warranties relate to an earlier date (in which case such representations and
warranties will be true and correct as of such earlier date) (the “VIB Closing Certificate”); and 

  

	4.4.3	Deliver to Ampio a duly executed consent from Ethypharm to the assignment by VIB to Ampio of the NDA Agreement, in a form substantially similar to the consent attached
hereto as Exhibit D (the “Ethypharm Consent”). 

 ARTICLE 5 

COVENANTS 

5.1     Further Assurances. VIB hereby agrees that it will promptly do all such acts and execute all such further documents,
conveyances, deeds, assignments, transfers, licenses, and the like, and will cause the doing of all such acts on its own behalf and by each of its Affiliates and will cause the execution of all such further documents on its own behalf and by each of
its Affiliates as are within its power as Ampio may from time to time reasonably request be done and/or executed in order to consummate the transactions contemplated under this Agreement, as may be necessary or desirable to effect the purposes of
this Agreement, or as may be appropriate to more effectively carry out and vest in Ampio the grant of rights and licenses intended to be made under this Agreement. 
 5.2     Technology Transfer. No later than sixty (60) days after the Closing Date, VIB shall use commercially reasonable efforts to make available to Ampio the Tramadol Know-How (or copies thereof) identified as “essential” in the Technology Transfer Plan. The Parties agree that, if VIB is unable to make available to Ampio all of the Tramadol Know-How identified as “essential” in the Technology Transfer Plan within such sixty (60) day period, then the Parties shall meet to discuss, in good faith, alternate arrangements for the transfer of
such Tramadol Know-How. In addition, during such sixty (60) day period, VIB shall use commercially reasonable efforts to transfer to Ampio any Tramadol Know-How (or copies thereof) identified

  
 10 

 
as “non-essential” in the Technology Transfer Plan; provided however that Ampio agrees and acknowledges that certain of such “non-essential” Tramadol Know-How may not be easily obtainable by or on behalf of VIB and that, provided that VIB complies with its obligations under this Section 5.2, that it is not required to provide to Ampio copies of all of such
“non-essential” Tramadol Know-How and that if VIB fails to transfer all of such “non-essential” Tramadol Know-How to Ampio that it shall not in any
way prevent, delay or otherwise impact the payment by Ampio of the Initial Consideration to VIB. Ampio shall reimburse VIB for its reasonable costs of complying with such Technology Transfer Plan; provided VIB informs Ampio and obtains Ampio’s
approval prior to incurring such costs. For the purposes of this Section 5.2, “commercially reasonable efforts” shall include VIB making a request of its third party service providers and suppliers (including suppliers of raw
materials), engaged in connection with the [***] studies known to VIB as [***], to provide copies of any Tramadol Know-How in their possession. 
 5.3     Technology Transfer Assistance from Ampio. Ampio agrees to provide reasonable assistance to VIB in connection with the transfer of the Tramadol Know-How to Ampio, including by making available certain representatives of Ampio to assist VIB in conducting searches of certain materials located at the VIB facilities. 

5.4     NDA Agreement. No later than the earlier of (i) five (5) Business Days prior to the Closing and
(ii) VIB obtaining an Ethypharm Consent executed on behalf of Ethypharm, VIB shall provide Ampio with a complete, unredacted copy of the NDA Agreement. 
 5.5     Samples. Within thirty (30) days of Closing, VIB shall deliver the Samples to Ampio, as instructed by Ampio. Ampio shall be responsible for all reasonable costs of
VIB in delivering such Samples to Ampio or the facilities designated by Ampio. 
 5.6     Confidentiality. VIB
undertakes with Ampio, and Ampio undertakes with VIB, to keep confidential (except as expressly provided in this Agreement) at all times after the Closing Date, and not directly or indirectly reveal, disclose or use for its own or any other purposes
unrelated to its performance or the enforcement of its rights hereunder, any confidential information received or obtained as a result of entering into or performing, or supplied by or on behalf of a Party in the negotiations leading to, this
Agreement and which relates to: (i) the negotiations relating to this Agreement; or (ii) the subject matter and/or provisions of this Agreement. The prohibition in this Section 5.6 does not apply if: (i) the information was in
the public domain before it was furnished to the relevant Party or, after it was furnished to that Party, entered the public domain otherwise than as a result of (x) a breach by that Party of this Section 5.6 or any other confidentiality
agreement which that Party is bound or (y) a breach of a confidentiality obligation by the disclosure by a Third Party where the breach was previously known to that Party; or (ii) disclosure is necessary in order to comply with Applicable
Law, provided that any such information discloseable pursuant to this Section 5.6 shall be disclosed only to the extent required by Applicable Law and, unless such consultation is prohibited by Applicable Law or is not reasonably practicable,
only after consultation with VIB or Ampio (as the case may be). The Parties acknowledge and agree that Ampio shall be entitled to disclose this Agreement in its 
  

 

	*	Confidential Information, indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission. 

  
 11 

 
filings with the United States Securities and Exchange Commission; provided however that, no less than five (5) Business Days prior to the filing of this Agreement with the United States
Securities and Exchange Commission, Ampio provides VIB with a copy of the Agreement to be filed, including any proposed redactions to the provisions of such Agreement, and Ampio will consider, acting reasonably, the inclusion in such filing of any
additional redactions to the provisions of the Agreement that VIB reasonably requests. 
 5.7     Interim Covenants.
From and after the date hereof and until the Closing, except (i) as otherwise expressly contemplated by this Agreement or (ii) as permitted by the prior written consent of Ampio, (a) VIB will pay or perform all obligations relating to
the NDA Agreement as they become due and owing in the ordinary course of business, (b) VIB will not take (or omit to take) any action or enter into any transaction which, if effected before the date of this Agreement, would constitute a breach
of the representations, warranties or agreements of VIB contained in this Agreement; and (c) VIB will not take (or omit to take) any action or enter into any transaction which would prevent or delay the consummation of the transactions
contemplated under this Agreement. 
 5.8     Covenant Not To Sue. Notwithstanding anything to the contrary contained
in this Agreement, from and after the Closing, VIB shall not, and shall cause its Affiliates not to, sue or bring an action or proceeding seeking to enforce any intellectual property rights to prevent or restrict Ampio or its Affiliates, licensees
or subcontractors (i) from developing, manufacturing, importing, using, marketing, commercializing, distributing, or selling Tramadol Products anywhere in the world, (ii) from developing, manufacturing, importing, using, marketing,
commercializing, distributing, or selling an Ampio Product with the Active Ingredient as the sole active ingrendient and for use in the indication of premature ejaculation anywhere in the world or (iii) from using, utilizing or otherwise
exploiting the Tramadol Know-How or other Purchased Assets, and the rights, titles and interests thereto and therein, in connection with the development, manufacture, importation, use, marketing,
commercialization, distribution, or sale of an Ampio Product anywhere in the world; provided however that this Section 5.8 shall not operate to prevent VIB from bringing any claims for indemnification against Ampio that it is entitled to bring
pursuant to Article 8. 
 5.9     Regulatory or Governmental Audits. The Parties agree that each shall
cooperate with respect to any audit or inspection by Governmental Entity regarding the Tramadol Product or the Ampio Product, as the case may be. In particular, each Party shall grant access to such Governmental Entity to the books and records
related to the Tramadol Products, in the case of VIB, and related to the Ampio Products, in the case of Ampio, in each case in such Parties’ possession or control for the purposes of such audit or inspection.  

5.10     No Other Ongoing Obligations of VIB. Ampio acknowledges that, except as expressly set out herein, VIB shall have no
responsibilities or obligations with respect to the development, registration, marketing, distribution, manufacturing and sale of the Ampio Product. 
 ARTICLE 6 
 REPRESENTATIONS AND WARRANTIES OF VIB 

 

	6.1	VIB hereby represents and warrants to Ampio as follows: 

  
 12 

	6.1.1	Organization; Good Standing. VIB is a society with restricted liability, duly organized, validly existing and in good standing under the laws of Barbados and is
in good standing in every jurisdiction where the nature of the business conducted by it makes such qualification necessary, except where the failure to so qualify or be in good standing would not have a material adverse effect on VIB or its ability
to perform its obligations hereunder. 

  

	6.1.2	Authority; Execution and Delivery. VIB has the requisite power and authority to enter into the Agreement and the Transaction Documents and to consummate the
transactions contemplated hereby. The execution and delivery of the Agreement and the Transaction Documents by VIB and the consummation of the transactions contemplated hereby have been duly and validly authorized. The Agreement has been duly
executed and delivered by VIB and, assuming the due authorization, execution and delivery of the Agreement by Ampio, constitutes the legal, valid and binding obligation of such entity, enforceable against it in accordance with its terms, subject to
general principles of equity, including principles of commercial reasonableness, good faith and fair dealing (regardless of whether enforcement is sought in a proceeding at law or in equity). 

 

	6.1.3	Consents; No Violation, Etc. The execution and delivery of the Agreement do not, and the consummation of the transactions contemplated hereby and the compliance
with the terms hereof will not (a) violate any Applicable Law applicable to VIB in the Territory, (b) conflict with any provision of the certificate of organization or by-laws of VIB, or
(c) conflict with any material agreement to which VIB is a party or by which it is otherwise bound or (d) require any approval, authorization, consent, license, exemption, filing or registration with any court, arbitrator or Governmental
Entity. 

  

	6.1.4	Purchased Assets. VIB has good and valid title to all of the Purchased Assets, free and clear of any mortgage, charge, lien, security interest, easement, right
of way, pledge or encumbrance of any nature whatsoever. 

  

	6.1.5	NDA Agreement. The NDA Agreement is in full force and effect and constitutes a legal, valid and binding agreement of VIB and Ethypharm, enforceable in accordance
with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, and (ii) as limited by laws relating to
the availability of specific performance, injunctive relief or other equitable remedies. VIB has not received written notice that it is in default under, or in breach of, the NDA Agreement. To the Knowledge of VIB, Ethypharm is not in default under,
or in breach of, the NDA Agreement. VIB has the right to assign the NDA Agreement, subject to obtaining the Ethypharm Consent. 

  

	6.1.6	Litigation. There is no suit, claim, action, investigation or proceeding pending against VIB or, to the actual knowledge of VIB, threatened against VIB that
relates to the subject matter of this Agreement or the transactions contemplated hereby, which (a) if adversely determined, would result in a material adverse effect on the assets, rights and licenses being transferred hereby, taken as a whole,
or (b) challenges or seeks to prevent or enjoin the transactions contemplated by the Agreement. 

  
 13 

	6.1.7	Samples. The Samples were part of one or more batches of Tramadol Product manufactured by or on behalf of VIB and used by VIB in clinical trials [***]. The
Samples have been stored by VIB under substantially the same conditions as those under which VIB stores clinical trial material for its own clinical trials. 

 6.2     Limited Warranty. Except as expressly set forth in this Agreement and the NDA Agreement, the Purchased Assets are provided by VIB without warranty of merchantability or
fitness for a particular purpose or any other warranty of any kind, express or implied. Except for the express representations and warranties contained in this Agreement, VIB does not make any representations or warranties whatsoever. Additionally,
VIB makes no express or implied representations or warranties that the Purchased Assets will not infringe any patent, copyright, trademark or other rights. 
 ARTICLE 7 
 REPRESENTATIONS AND WARRANTIES OF AMPIO 

 

	7.1	Ampio hereby represents and warrants to VIB as follows: 

  

	7.1.1	Organization; Good Standing. Ampio is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and is in good
standing in every jurisdiction where the nature of the business conducted by it makes such qualification necessary, except where the failure to so qualify or be in good standing would not have a material adverse effect on Ampio or its ability to
perform its obligations hereunder. 

  

	7.1.2	Authority; Execution and Delivery. Ampio has the requisite corporate power and authority to enter into the Agreement and the Transaction Documents and to
consummate the transactions contemplated hereby. The execution and delivery of the Agreement and the Transaction Documents by Ampio and the consummation of the transactions contemplated hereby have been duly and validly authorized. The Agreement has
been duly executed and delivered by Ampio and, assuming the due authorization, execution and delivery of the Agreement by VIB, constitutes the legal, valid and binding obligation of Ampio, enforceable against Ampio in accordance with its terms,
subject to general principles of equity, including principles of commercial reasonableness, good faith and fair dealing (regardless of whether enforcement is sought in a proceeding at law or in equity). 

 

	7.1.3	Consents; No Violations, Etc. The execution and delivery of the Agreement do not, and the consummation of the transactions contemplated hereby and the compliance
with the terms hereof will not (a) violate any Applicable Law applicable to Ampio, (b) conflict with any provision of the articles of incorporation or bylaws of Ampio, (c) conflict with any material agreement to which Ampio is a party
or by which it is otherwise bound or (d) require any approval, authorization, consent, license, exemption, filing or registration with any court, arbitrator or Governmental Entity. 

 
  

	*	Confidential Information, indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission. 

  
 14 

	7.1.4	Litigation. There is no suit, claim, action, investigation or proceeding pending against Ampio or, to the actual knowledge of Ampio, threatened against Ampio,
that challenges or seeks to prevent or enjoin the transactions contemplated by the Agreement. 

 ARTICLE 8

 SURVIVAL OF REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION 

8.1     Survival. All representations and warranties of VIB and Ampio contained herein or made pursuant hereto shall survive
the Effective Date for a period of twelve (12) months after the Effective Date. The covenants and agreements of the Parties contained in the Agreement shall survive and remain in full force for the applicable periods described therein or, if no
such period is specified, for twelve (12) months after the Effective Date. Any right of indemnification pursuant to Article 8 hereof with respect to a claimed breach of a (a) representation or warranty shall expire at the date of
termination of the representation or warranty claimed to be breached, and (b) covenant shall expire one (1) year after the date of termination of the covenant claimed to be breached, unless in both cases on or prior to such date the Party
from whom indemnification is sought shall have received notice in accordance with the provisions of Section 8.4 hereof. The provisions of this Section 8.1 shall survive for so long as any other Section of the Agreement shall survive.

 8.2     Indemnification by VIB. VIB hereby agrees to indemnify Ampio and its Affiliates and their respective
officers, directors and employees (the “Ampio Indemnified Parties”) against, and agrees to hold them harmless from, any Loss to the extent such Loss arises from or in connection with (i) any breach by or on behalf of VIB of any
representation or warranty contained in the Agreement, (ii) any breach by or on behalf of VIB of any of its covenants contained in the Agreement, (iii) the negligence or willful misconduct of VIB or VIB’s Affiliates, or (iv) the
Retained Liabilities; except, in each case, to the extent that such Losses are attributable to any of the matters for which Ampio is required to indemnify the VIB Indemnified Parties pursuant to Section 8.3. 

8.3     Indemnification by Ampio. Ampio hereby agrees to indemnify VIB and its Affiliates and their respective officers,
directors and employees (the “VIB Indemnified Parties”) against, and agrees to hold them harmless from, any Loss to the extent such Loss arises from or in connection with (i) any breach by or on behalf of Ampio of any
representation or warranty contained in the Agreement, (ii) any breach by or on behalf of Ampio of any covenant contained in the Agreement, (iii) the negligence or willful misconduct of Ampio or Ampio’s Affiliates, (iv) the
development, manufacture, distribution, marketing, sale or use of the Ampio Product on or after the Closing Date, (v) any Product Liability Claims or other claims asserted by Third Parties related to the Ampio Product, except to the extent such
other claims arise from events, acts or omissions occurring prior to the Closing Date, or (vi) the Assumed Liabilities; except, in each case, to the extent that such Losses are attributable to any of the matters for which VIB is required to
indemnify the Ampio Indemnified Parties pursuant to Section 8.2. 

  
 15 

	8.4	Procedure. 

  

	8.4.1	Indemnification Process Generally. In order for an indemnified party under this Article 8 (an “Indemnified Party”) to be entitled to any
indemnification provided for under the Agreement, such Indemnified Party shall, promptly following the discovery of the matters giving rise to any Loss, notify the indemnifying party under this Article 8 (the “Indemnifying
Party”) in writing of its claim for indemnification for such Loss, specifying in reasonable detail the nature of such Loss and the amount of the liability estimated to accrue therefrom; provided, however, that failure to give such prompt
notification shall not affect the indemnification provided hereunder except to the extent the Indemnifying Party shall have been actually prejudiced as a result of such failure (except that the Indemnifying Party shall not be liable for any expenses
incurred during the period in which the Indemnified Party failed to give such notice). Thereafter, the Indemnified Party shall deliver to the Indemnifying Party, within five (5) Business Days after the Indemnified Party’s receipt of such
request, all information and documentation reasonably requested by the Indemnifying Party with respect to such Loss. 

  

	8.4.2	 Third Party Claims. If the indemnification sought pursuant hereto involves a claim made by a Third Party against the Indemnified Party (a
“Third Party Claim”), the Indemnifying Party shall be entitled to participate in the defense of such Third Party Claim and, if it so chooses, to assume the defense of such Third Party Claim with counsel selected by the Indemnifying
Party. Should the Indemnifying Party so elect to assume the defense of a Third Party Claim, the Indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by the Indemnified Party in connection with
the defense thereof. If the Indemnifying Party assumes such defense, the Indemnified Party shall have the right to be represented in the defense thereof and to employ counsel, at its own expense, separate from the counsel employed by the
Indemnifying Party, it being understood that the Indemnifying Party shall control such defense. The Indemnifying Party shall be liable for the reasonable fees and expenses of counsel employed by the Indemnified Party for any period during which the
Indemnifying Party has not assumed the defense thereof (other than during any period in which the Indemnified Party shall have failed to give notice of the Third Party Claim as provided above). If the Indemnifying Party chooses to defend or
prosecute a Third Party Claim, the other party hereto shall cooperate in the defense or prosecution thereof. Such cooperation shall include the retention and (upon the Indemnifying Party’s request) the provision to the Indemnifying Party of
records and information which are reasonably relevant to such Third Party Claim, and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. If the Indemnifying
Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party will agree to any settlement, compromise or discharge of such Third Party Claim which the Indemnifying Party may recommend and which by its terms (i) obligates
the Indemnifying Party to pay the full amount of the liability in connection with such Third Party Claim, (ii) includes a full release in favor of the Indemnified Party with respect to the Third Party Claim, does not include any admission of
liability and contains reasonable provisions maintaining the confidentiality of the 

  
 16 

	 	
settlement, compromise or discharge, and (iii) does not impair the rights of the Indemnified Party. Whether or not the Indemnifying Party shall have assumed the defense of a Third Party
Claim, the Indemnified Party shall not admit any liability with respect to, or settle, compromise or discharge, such Third Party Claim without the Indemnifying Party’s prior written consent, which will not be unreasonably withheld or delayed.

  

	8.5	Certain Limitations on Indemnification. 

  

	8.5.1	Indirect Damages. IN NO EVENT SHALL ANY PARTY, ITS DIRECTORS, OFFICERS, EMPLOYEES, AGENTS OR AFFILIATES BE LIABLE TO THE OTHER PARTIES FOR ANY INDIRECT,
INCIDENTAL, SPECIAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES, WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR OTHERWISE, ARISING OUT OF THIS AGREEMENT; provided that such limitation on liability
shall not apply to Third Party Claims, as such damages shall be deemed direct damages notwithstanding the characterization of such damages in the underlying Third Party Claim. 

 

	8.5.2	Notwithstanding anything to the contrary contained herein, in no event shall the aggregate indemnification to paid by VIB hereunder exceed the aggregate amount of
Initial Consideration and Additional Consideration actually paid by Ampio to VIB at such time. 

 ARTICLE 9

 TERMINATION 
 9.1     Termination by Ampio. Following the good faith discussions described in Section 5.2, if VIB has failed to transfer to Ampio all of the Tramdaol Know-How identified as “essential” in the Technology Transfer Plan within sixty (60) days of the Effective Date (or such longer period as agreed to by the Parties) and the Parties have not agreed to
alternate arrangements with respect to the transfer of the Tramadol Know-How, then Ampio shall have the right to terminate this Agreement in accordance with Section 9.3. If Ampio so terminates, then it shall have no obligation to pay to VIB the
Initial Consideration or the Additional Consideration. 
 9.2     Termination by VIB. If Ampio has failed to pay to
VIB the Initial Consideration when due, VIB shall have the right to terminate this Agreement in accordance with Section 9.3. If VIB so terminates, then Ampio shall have no obligation to pay to VIB the Initial Consideration or the Additional
Consideration. 
 9.3     Effect of Termination by VIB. In the event of a termination of this Agreement by Ampio or
VIB pursuant to Section 9.1 or 9.2, respectively, Ampio shall assign, convey, transfer and deliver all right, title and interest in the Purchased Assets sold, assigned, transferred and conveyed by VIB to Ampio pursuant to Section 2.1 of
this Agreement and Ampio undertakes to: 

  
 17 

	9.3.1	return to VIB, within thirty (30) days of the effective date of termination, all documents and data containing Confidential Information of VIB disclosed by Ampio;

  

	9.3.2	return to VIB, within thirty (30) days of the effective date of termination, all documents, materials, information and data containing or constituting Tramadol
Know-How; 

  

	9.3.3	cease utilizing the Purchased Assets anywhere in the Territory; 

  

	9.3.4	assign the NDA Agreement to VIB or VIB’s designee, as instructed by VIB; and 

 

	9.3.5	destroy or return, at the discretion of VIB, any and all remaining Samples held by or in the possession or control of Ampio or its Affiliates or sublicensees or
subcontractors and, within thirty (30) days of the effective date of termination, provide a certificate to VIB certifying to such destruction or return. 

 With respect to the assignment of the NDA Agreement from Ampio to VIB pursuant to Section 9.3.4, pending receipt of the consent of Ethypharm to such assignment, the Parties shall cooperate with each
other in any mutually agreeable, reasonable and lawful arrangements designed to provide to VIB the benefits of use of the NDA Agreement that it would have obtained had the NDA Agreement been assigned to VIB at the effective date of termination of
this Agreement. As of the effective date of the termination of the Agreement and until the NDA Agreement has been assigned to VIB, Ampio shall not take any action under the NDA Agreement without obtaining the prior written consent of VIB and shall
take all reasonable actions at VIB’s cost in relation to the NDA Agreement requested by VIB. If any such consent cannot be obtained within ninety (90) days of the effective date of the termination, Ampio shall use its commercially
reasonable efforts to obtain for VIB substantially all of the practical benefit and burden of the NDA Agreement, including by entering into appropriate and reasonable alternative arrangements on terms mutually agreeable to VIB and Ampio. 

9.4     Survival. If Ampio or VIB terminates this Agreement pursuant to Section 9.1 or 9.2, the following provisions of
this Agreement shall survive: Sections 5.6 and 9.3, this Section 9.4 and Articles 6, 7, 8 and 10. In any event, termination of this Agreement shall not relieve the Parties of any liability which accrued hereunder prior to the effective date of
such termination. 
 ARTICLE 10 
 MISCELLANEOUS 
 10.1     Notices. All notices or other
communications hereunder shall be deemed to have been duly given and made if in writing and if served by personal delivery upon the party for whom it is intended, delivered by registered or certified mail, return receipt requested, or by a national
overnight courier service, or sent by facsimile, to the Person at the address or facsimile number set forth below, or such other address as may be designated in writing hereafter, in the same manner, by such Person: 

  
 18 

 To VIB: 

        Valeant International (Barbados) SRL 

        Welches Christ Church 

        Barbados, BB17154 

        Facsimile: (246) 420-1532

         Attention: President 

To Ampio: 
         Ampio Pharmaceuticals, Inc. 
         5445 DTC Parkway, Suite 925 
         Greenwood Village, Colorado 80111 
         Facsimile: 720-437-6501 

        Attention: Chief Executive Officer 

With a required copy to: 
         Goodwin Procter LLP 
         Exchange Place 

        53 State Street 

        Boston, Massachusetts 02109 

        Attention: Lawrence Wittenberg, Esq. 

        Facsimile: 617-523-1231 
 All notices and other communications under this Agreement shall be deemed to have been
received (i) when delivered by hand, if personally delivered, (ii) three (3) Business Days after being delivered by registered or certified mail, return receipt requested, (iii) one (1) Business Day after being delivered to
a national overnight courier service or (iv) on the date of receipt, if sent by facsimile. 
 10.2     Amendment;
Waiver. Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed (i) in the case of an amendment, by VIB and Ampio, and (ii) in the case of a waiver, by the Party
against whom the waiver is to be effective. No failure or delay by either Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further
exercise thereof or the exercise of any other right, power or privilege. 
 10.3     Assignment. The terms and
provisions of this Agreement shall inure to the benefit of, and be binding upon, the Parties and their respective successors and permitted assigns. Neither Party shall assign or otherwise transfer this Agreement or its rights and obligations
thereunder without the prior written consent of the other Party, provided that no such consent shall be required in connection with an assignment or transfer upon a sale of all or substantially all of the assets of the Party to a Third Party. In
addition, either Party may, on notice to the other Party, assign, sublicense, subcontract or delegate all or any of its rights and obligations under this Agreement to an Affiliate, so long as the assigning or transferring Party remains fully
responsible for the performance of its Affiliate. 

  
 19 

 10.4     Entire Agreement. This Agreement, together with the Transaction
Document, contains the entire agreement among the Parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters. 

10.5     Public Disclosure. Notwithstanding anything herein to the contrary, each Party hereby agrees with the other Party,
except as may be required to comply with the requirements of any Applicable Law or the rules and regulations of each stock exchange upon which the securities of such Party are listed, if any, (in which case such Party shall notify without delay the
other Party and provide the other Party with a copy of the contemplated disclosure prior to submission or release, as the case may be, unless notifying is impracticable due to circumstances beyond such Party’s control) that no press release or
similar public announcement or communication shall, at any time, be made by it or caused to be made by it concerning the execution or performance of this Agreement unless it shall have consulted the other Party in advance with respect thereto and
such other Party consents in writing to such release, announcement or communication. 
 10.6     Expenses. Except as
otherwise provided in this Agreement, whether or not the Closing takes place, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the Party incurring such costs and expenses.

 10.7     Governing Law; Jurisdiction; No Jury Trial. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York, without regard to any conflicts of law principles thereof to the extent such principles would permit or require the application of the laws of another jurisdiction. The Parties consent to the
exclusive jurisdiction of the Federal and State courts located in New York City, New York. Each of the Parties (i) consents to the jurisdiction of each such court in any such suit, action or proceeding, (ii) waives any objection that it
may have to the laying of venue in any such suit, action or proceeding in any such court and (iii) agrees that service of any court paper may be made in such manner as may be provided under applicable Laws or court rules governing service of
process. THE PARTIES HERETO HEREBY IRREVOCABLY WAIVE, AND AGREE TO CAUSE THEIR RESPECTIVE AFFILIATES TO WAIVE, THE RIGHT TO TRIAL BY JURY IN ANY SUCH ACTION PERMITTED HEREUNDER. 
 10.8     Severability. The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or
enforceability of the other provisions hereof. If any term or other provision of this Agreement, or the application thereof to any Person or any circumstance, is invalid, illegal or unenforceable, (a) a suitable and equitable provision shall be
substituted therefore in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the remainder of this Agreement and the application of such provision to other
Persons or circumstances shall not be affected by such invalidity, illegality or unenforceability, nor shall such invalidity, illegality or unenforceability affect the validity or enforceability of such provision, or the application thereof, in any
other jurisdiction. 

  
 20 

 10.9     Execution and Delivery. This Agreement may be executed by the Parties in
counterparts and may be executed and delivered by facsimile or e-mail transmissions and all such counterparts, (whether original, e-mail or facsimile) together
constitute one and the same agreement. 
 [signature page follows] 

  
 21 

 IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by a duly authorized
representative of each of VIB and Ampio as of the Effective Date. 
 AMPIO PHARMACEUTICALS, INC.

  

			
	
		
	By:	 	/s/ Don Wingerter
	Name: Don Wingerter
	Title:   CEO

 VALEANT INTERNATIONAL (BARBADOS) SRL 

 

			
	
		
	By:	 	/s/ Richard K. Masterson
	Name: Richard K. Masterson
	Title:   President and COO

  
 22 

 EXHIBIT A 
 Assumption Agreement 
 See attached. 

  
 23 

 ASSUMPTION OF LIABILITIES AGREEMENT 

THIS AGREEMENT made this             day of
            , 2011 
 B E T W E E N: 

AMPIO PHARMACEUTICALS, INC., a Delaware corporation (hereinafter referred to as “Ampio”) 

OF THE FIRST PART 

– and – 

VALEANT INTERNATIONAL (BARBADOS) SRL, a Barbados international society with restricted liability (hereinafter referred to as
“VIB”) 
 OF THE SECOND PART 
 WHEREAS pursuant to an Asset Purchase Agreement (the “Purchase Agreement”) between Ampio and VIB, dated December 2, 2011, Ampio agreed, among other things, to assume the Assumed Liabilities
(as the term is used in the PurchaseAgreement) of VIB; 
 AND WHEREAS the PurchaseAgreement calls for the delivery of this
Agreement. 
 NOW THEREFORE, in consideration of these premises, the covenants and agreements hereinafter set forth and other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto covenant and agree as follows: 
 1.     Capitalized Terms. All capitalized terms not otherwise defined herein shall have the meanings respectively assigned thereto in the Purchase Agreement. 

2.     Assignment and Assumption. VIB hereby assigns, transfers, conveys and delivers to Ampio, all of VIB’s
right, title and interest in, to and under the Assumed Liabilities, but specifically excluding the Retained Liabilities. Ampio hereby assumes the Assumed Liabilities as part of the consideration being paid in connection with the execution of the
PurchaseAgreement and the transactions contemplated thereby and agrees to duly and punctually observe and perform the covenants, provisos and conditions on the part of VIB pertaining to the Assumed Liabilities.Ampioassumes from VIB none of the
Retained Liabilities. 
 3.     Further Assurances. VIB agrees that it will at all times hereafter at the
request and expense of Ampio execute and deliver all such instruments of assignment, conveyance, endorsement or authorization and other documents or take such additional action as Ampio may reasonably require. 

4.     Enurement. This Agreement shall be binding upon and enure to the benefit of the Parties hereto and their
respective successors and permitted assigns. 

 5.     Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York, without regard to any conflicts of law principles thereof to the extent such principles would permit or require the application of the laws of another jurisdiction. The Parties consent to the
exclusive jurisdiction of the Federal and State courts located in New York City, New York. Each of the Parties (i) consents to the jurisdiction of each such court in any such suit, action or proceeding, (ii) waives any objection that it
may have to the laying of venue in any such suit, action or proceeding in any such court and (iii) agrees that service of any court paper may be made in such manner as may be provided under applicable Laws or court rules governing service of
process. THE PARTIES HERETO HEREBY IRREVOCABLY WAIVE, AND AGREE TO CAUSE THEIR RESPECTIVE AFFILIATES TO WAIVE, THE RIGHT TO TRIAL BY JURY IN ANY SUCH ACTION PERMITTED HEREUNDER. 
 6.     Execution and Delivery. This Agreement may be executed by the Parties in counterparts and may be executed and delivered by facsimile or e-mail transmissions and all such counterparts, (whether original, e-mail or facsimile) together constitute one and the same agreement. 

[signature page follows] 

  
 2 

 IN WITNESS WHEREOF the Parties hereto have executed this Agreement on the date first above
written. 
  

			
	AMPIO PHARMACEUTICALS, INC.
		
	Per:	 	 
	 Name:

Title:

  

			
	 VALEANT INTERNATIONAL

(BARBADOS) SRL

		
	Per:	 	 
	 Name:

Title:

  
 3 

 EXHIBIT B 
 Bill of Sale 
 See attached. 

 BILL OF SALE 

THIS AGREEMENT made this             day of
            , 2011 
 B E T W E E N: 

AMPIO PHARMACEUTICALS, INC., a Delaware corporation (hereinafter referred to as “Ampio”) 

OF THE FIRST PART 

– and – 

VALEANT INTERNATIONAL (BARBADOS) SRL, a Barbados international society with restricted liability (hereinafter referred to as
“VIB”) 
 OF THE SECOND PART 
 WITNESSES THAT: 
 WHEREAS pursuant to an Asset Purchase Agreement (the
“Purchase Agreement”) between Ampio and VIB, dated December 2, 2011, among other things, VIB agreed to sell and Ampio agreed to purchase the Samples and the Tramadol Know-How; 

AND WHEREAS the Purchase Agreement calls for the delivery of this Bill of Sale; 

NOW THEREFORE, in consideration of these premises, the covenants and agreements hereinafter set forth and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto covenant and agree as follows: 

1.         All capitalized terms not otherwise defined herein shall have the meanings respectively assigned
thereto in the Purchase Agreement. 
 2.          VIB does hereby bargain, sell, assign, transfer,
convey, deliver and set over unto Ampio, effective as of the date hereof, all of VIB’s right, title and interest in and to the Samples and the Tramadol Know-How. 
 3.          Ampio hereby purchases, accepts and acquires from VIB the Samples and the Tramadol Know-How. 

4.          The Parties hereto covenant and agree that they will from time to time and at all times
hereafter, upon the reasonable request of the other Party but at the expense of the other Party, make, do and execute or cause and procure to be made, done and executed all such further acts, deeds or assurances as may be reasonably required by the
other party to carry out the true intent and meaning of this Agreement fully and effectually. 

5.          This Agreement shall in no way limit, derogate from or otherwise affect and is without prejudice
to the covenants, agreements, representations, warranties, indemnities and obligations contained in the PurchaseAgreement, all of which shall continue in full force and effect for their benefit in accordance with the terms of the PurchaseAgreement.

 6.          This Agreement shall be governed by and construed
in accordance with the laws of the State of New York, without regard to any conflicts of law principles thereof to the extent such principles would permit or require the application of the laws of another jurisdiction. The Parties consent to the
exclusive jurisdiction of the Federal and State courts located in New York City, New York. Each of the Parties (i) consents to the jurisdiction of each such court in any such suit, action or proceeding, (ii) waives any objection that it
may have to the laying of venue in any such suit, action or proceeding in any such court and (iii) agrees that service of any court paper may be made in such manner as may be provided under applicable Laws or court rules governing service of
process. THE PARTIES HERETO HEREBY IRREVOCABLY WAIVE, AND AGREE TO CAUSE THEIR RESPECTIVE AFFILIATES TO WAIVE, THE RIGHT TO TRIAL BY JURY IN ANY SUCH ACTION PERMITTED HEREUNDER. 
 7.          This Agreement shall enure to the benefit of and be binding upon the Parties hereto and their respective successors and assigns. 

8.          This Agreement may be executed by the Parties in counterparts and may be executed and delivered
by facsimile or e-mail transmissions and all such counterparts, (whether original, e-mail or facsimile) together constitute one and the same agreement. 

[signature page follows] 

  
 2 

 IN WITNESS WHEREOF VIB and Ampio have duly executed this Bill of Sale as of the date set out
above. 
  

			
	AMPIO PHARMACEUTICALS, INC.
		
	Per:	 	 
	 Name:

Title:

  

			
	 VALEANT INTERNATIONAL
 (BARBADOS) SRL

		
	Per:	 	 
	 Name:

Title:

  
 3 

 EXHIBIT C 
 Contract Assignment and Assumption Agreement 
 See attached. 

 CONTRACT ASSIGNMENT AND ASSUMPTION AGREEMENT 

THIS AGREEMENT made this             day of
            , 2011 
 BETWEEN: 

AMPIO PHARMACEUTICALS, INC., a Delaware corporation (hereinafter referred to as “Ampio”) 

OF THE FIRST PART 

– and – 

VALEANT INTERNATIONAL (BARBADOS) SRL, a Barbados international society with restricted liability (hereinafter referred to as
“VIB”) 
 OF THE SECOND PART 
 WHEREAS pursuant to an Asset Purchase Agreement (the “Purchase Agreement”) between Ampio and VIB, dated December 2, 2011, VIB agreed, among other things, to assign to Ampio the NDA
Agreement (as defined in the Purchase Agreement); 
 AND WHEREAS the Purchase Agreement calls for the delivery of this
Agreement; 
 NOW THEREFORE, in consideration of these premises, the covenants and agreements hereinafter set forth and other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto covenant and agree as follows: 
 1.          Capitalized Terms. All capitalized terms not otherwise defined herein shall have the meanings respectively assigned thereto in the
Purchase Agreement. 
 2.          Assignment. In accordance with and subject to the
terms of the Purchase Agreement, VIB hereby sells, assigns and transfers to Ampio effective as of the date hereof, the NDA Agreement, together with all of its rights and privileges and benefits to be derived therefrom, including the full power and
authority to enforce the performance of the covenants and other matters and things contained in the NDA Agreement. 

3.          Assumption. In accordance with and subject to the terms of the Purchase Agreement,
Ampio hereby assumes all of VIB’s obligations and liabilities arising under the NDA Agreement arising from and after the Closing Date and agrees to duly and punctually observe and perform the covenants, provisos and conditions on the part of
VIB contained in the NDA Agreementarising from and after the Closing Date. 
 4.         
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to any conflicts of law principles thereof to the extent such principles would permit or require the
application of the laws of another jurisdiction. The Parties consent to the exclusive jurisdiction of the Federal and State courts 

 
located in New York City, New York. Each of the Parties (i) consents to the jurisdiction of each such court in any such suit, action or proceeding, (ii) waives any objection that it may
have to the laying of venue in any such suit, action or proceeding in any such court and (iii) agrees that service of any court paper may be made in such manner as may be provided under applicable Laws or court rules governing service of
process. THE PARTIES HERETO HEREBY IRREVOCABLY WAIVE, AND AGREE TO CAUSE THEIR RESPECTIVE AFFILIATES TO WAIVE, THE RIGHT TO TRIAL BY JURY IN ANY SUCH ACTION PERMITTED HEREUNDER. 
 5.          Further Assurances. VIB agrees that it will at all times hereafter at the request and expense of Ampio execute and deliver all such
further assurances in respect of this Agreement as Ampio may reasonably require. 
 6.         
Enurement. This Agreement shall be binding upon and enure to the benefit of the Parties hereto and their respective successors and permitted assigns. 
 7.          Execution and Delivery. This Agreement may be executed by the Parties in counterparts and may be executed and delivered by facsimile
or e-mail transmissions and all such counterparts, (whether original, e-mail or facsimile) together constitute one and the same agreement. 

[signature page follows] 

  
 2 

 IN WITNESS WHEREOF the Parties have caused this Agreement to be executed as of the
date first above written. 
  

			
	AMPIO PHARMACEUTICALS, INC.
		
	Per:	 	 
	 Name:

Title:

  

			
	 VALEANT INTERNATIONAL

(BARBADOS) SRL

		
	Per:	 	 
	 Name:

Title:

  
 3 

 EXHIBIT D 
 Ethypharm Consent 

1.         Effective as of the Closing Date, Ethypharm hereby consents to and accepts the
assignment by VIB of the NDA Agreement to Ampio. 
 2.         [***] 

IN WITNESS WHEREOF, this Consent To Assignment has been duly executed and delivered by a duly authorized representative of Ethypharm and
VIB as of the Closing Date. 
  

									
	ETHYPHARM	 		 	VALEANT INTERNATIONAL (BARBADOS) SRL
					
	By:	 	 	 		 	By:	 	 
	Name:	 		 		 	Name:	 	
	 Title:
	 		 		 	 Title:
	 	

  
  

	*	Confidential Information, indicated by [***] has been omitted from this filing and filed separately with the Securities Exchange Commission.EX-10.5

 Exhibit 10.5 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934. 

Execution Copy 
 MANUFACTURING AND SUPPLY AGREEMENT 
 by and between 

ETHYPHARM S.A. 
 and 
 AMPIO PHARMACEUTICALS, INC. 

* * * 

 TABLE OF CONTENTS 

 
  

							
	 	  	 	  	Page	 
	 ARTICLE 1 DEFINITIONS
	  	 	4	  
		
	 ARTICLE 2 APPOINTMENT OF MANUFACTURER
	  	 	8	  
	 2.1
	  	Requirements	  	 	8	  
	 2.2
	  	Third Party Manufacturer	  	 	8	  
	 2.3
	  	Joint Manufacturing Committee	  	 	8	  
		
	 ARTICLE 3 REGULATORY AND QUALITY UNDERTAKINGS
	  	 	9	  
	 3.1
	  	Regulatory	  	 	9	  
	 3.2
	  	Import and Packaging	  	 	9	  
	 3.3
	  	Change in Specifications	  	 	9	  
	 3.4
	  	Advertising, Promotional Materials, and Public Statements	  	 	10	  
	 3.5
	  	Product Complaints and Adverse Drug Experiences	  	 	10	  
	 3.6
	  	Facility Maintenance; Inspection; Reports	  	 	10	  
	 3.7
	  	Filing Requirements and Maintenance	  	 	10	  
	 3.8
	  	Product Recall	  	 	11	  
	 3.9
	  	Quality Agreement	  	 	11	  
		
	 ARTICLE 4 FORECAST, ORDER, SUPPLY PRICE, SUPPLY INTERRUPTION
	  	 	12	  
	 4.1
	  	Forecast Reports	  	 	12	  
	 4.2
	  	Product Orders	  	 	12	  
	 4.3
	  	Batch Sizes of Product	  	 	12	  
	 4.4
	  	Inventories	  	 	12	  
	 4.5
	  	Supply Price of the Product	  	 	13	  
	 4.6
	  	Supply Interruption	  	 	13	  
	 4.7
	  	Deficiency Notice	  	 	14	  
	 4.8
	  	Determination of Deficiency	  	 	14	  
	 4.9
	  	Rejection for Deficiency	  	 	15	  
		
	 ARTICLE 5 WARRANTIES AND COVENANTS
	  	 	15	  
	 5.1
	  	Certain Representations and Warranties of Ethypharm	  	 	15	  
	 5.2
	  	Certain Representations and Warranties of Ampio	  	 	15	  
	 5.3
	  	Certain Covenants of Ampio	  	 	16	  
	 5.4
	  	Certain Covenants of Ethypharm	  	 	16	  
	 5.5
	  	Storage	  	 	16	  

							
	 5.6
	  	Representation and Warranties with Regard to Status	  	 	16	  
	 5.7
	  	Compliance with Specifications and cGMP	  	 	16	  
	 5.8
	  	Limitation of Warranty	  	 	17	  
		
	 ARTICLE 6 INDEMNIFICATION AND LIMITATION OF LIABILITY
	  	 	17	  
	 6.1
	  	Ethypharm’s Indemnification Obligations	  	 	17	  
	 6.2
	  	Ampio’s Indemnification Obligations	  	 	17	  
	 6.3
	  	Indemnification Procedures	  	 	17	  
	 6.4
	  	Limitation of Liability	  	 	18	  
		
	 ARTICLE 7 INSURANCE
	  	 	18	  
		
	 ARTICLE 8 CONFIDENTIALITY
	  	 	19	  
	 8.1
	  	Treatment of Confidential Information	  	 	19	  
	 8.2
	  	Limits on Disclosure	  	 	19	  
		
	 ARTICLE 9 TERM AND TERMINATION
	  	 	20	  
	 9.1
	  	Term	  	 	20	  
	 9.2
	  	Termination for Breach	  	 	20	  
	 9.3
	  	Termination for Bankruptcy	  	 	20	  
	 9.4
	  	Withdrawal of Regulatory Approval and NDA	  	 	20	  
	 9.5
	  	No Waiver of Termination Rights	  	 	20	  
		
	 ARTICLE 10 FORCE MAJEURE
	  	 	21	  
	 10.1
	  	Effects of Force Majeure	  	 	21	  
	 10.2
	  	Notice of Force Majeure	  	 	21	  
		
	 ARTICLE 11 Miscellaneous
	  	 	21	  
	 11.1
	  	Dispute Resolution	  	 	21	  
	 11.2
	  	Independent Contractors	  	 	22	  
	 11.3
	  	Assignment	  	 	22	  
	 11.4
	  	Governing Law	  	 	22	  
	 11.5
	  	No Implied Waiver	  	 	22	  
	 11.6
	  	Notice	  	 	22	  
	 11.7
	  	Amendments	  	 	23	  
	 11.8
	  	Counterparts	  	 	23	  
	 11.9
	  	Interpretation	  	 	24	  
	 11.10
	  	Entire Agreement	  	 	24	  
	 11.11
	  	Benefit; Binding Effect	  	 	24	  
	 11.12
	  	Survival	  	 	24	  
	 11.13
	  	Further Assurances	  	 	24	  
	 11.14
	  	Severability	  	 	24	  
	 11.15
	  	Use of Names; Publicity	  	 	25	  
		  		  			

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.
A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

  

 MANUFACTURING AND SUPPLY AGREEMENT 

THIS MANUFACTURING AND SUPPLY AGREEMENT (the “Agreement”), dated as of September 10, 2012 (the
“Effective Date”), is entered into by and between ETHYPHARM S.A., a corporation organized under the laws of France with an address at 194 Bureaux de la Colline, F92213 Saint-Cloud, France (“Ethypharm”), and AMPIO
PHARMACEUTICALS, INC., a corporation organized under the laws of the state of Delaware with an address at 5445 DTC Parkway, Suite 925, Greenwood Village, Colorado 80111, USA (“Ampio”). 

WHEREAS, Ethypharm and Valeant International (Barbados) SRL (formerly Biovail Laboratories International, SRL) (“Valeant”)
entered into that certain NDA Assignment and License Agreement dated as of February 6, 2009 (the “License Agreement”) under which Valeant was given rights from Ethypharm to use the Technology (as defined below) to develop and
commercialize the Product (as defined below) on a worldwide basis; 
 WHEREAS, pursuant to that certain Contract Assignment and
License Agreement, dated December 20, 2011, between Valeant and Ampio, Ampio was assigned all of Valeant’s rights under the License Agreement; 
 WHEREAS, pursuant to the terms of the License Agreement, Ampio has developed the Product and its related Regulatory Documentation (as defined below) and is in the process of registration of the Product in
different countries of the Territory (as defined below). 
 WHEREAS, pursuant to the terms of the License Agreement, Ampio has
engaged Ethypharm, who has accepted, as its exclusive manufacturer and supplier of the Product in the Territory; 
 NOW,
THEREFORE, in consideration of the foregoing premises and mutual covenants of the Parties hereinafter set forth, the parties agree as follows: 
 ARTICLE 1 
 DEFINITIONS 

“Affiliate” means, with respect to any Person, any other Person that (directly or indirectly) is controlled by,
controls, or is under common control with such Person. For purposes of this definition, the term “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”) as used with
respect to a Person means direct or indirect beneficial or legal ownership of more than fifty percent (50%) of the voting interest in, or more than fifty percent (50%) of the equity of or the right to appoint more than fifty percent
(50%) of the directors or managers of the corporation or other business entity or the power to direct or cause the direction of the management and policies of such corporation or entity, whether pursuant to the ownership of voting securities,
by contract or otherwise. 

 “cGMP” shall mean the practices required with respect to the manufacture of
the Product by the provisions of EC Commission Directive 2003/94/CE together with the Guide to Good Manufacturing Practice published by the EC Commission in 1992 (ISBN 92-826-3180-X) and by the Food and Drug Administration in the provisions of 21 C.F.R., parts 210 and 211. 
 “Commercial Manufacturing Site” means Ethypharm’s manufacturing site at Châteauneuf en Thymerais, France, or any other manufacturing site to be agreed upon by both parties
pursuant to the terms of this Agreement. 
 “Commercially Reasonable Efforts” means, with respect to the
efforts to be expended by a party with respect to any objective, reasonable, diligent, good faith efforts to accomplish such objective that such party would normally use to accomplish a similar objective under similar circumstances, it being
understood and agreed that with respect to the research, development or commercialization of the Product, such efforts shall be substantially equivalent to those efforts and resources commonly used by a party for a similar pharmaceutical product
owned by it or to which it has rights, which product is at a similar stage in its development or product life and is of similar market potential taking into account efficacy, safety, anticipated labeling, the competitiveness of alternative products
in the marketplace, the patent and other proprietary position of the product, the likelihood of regulatory approval, commercial value of the product, alternative products and other relevant factors. 

“Confidential Information” means all trade secrets, processes, formulae, data, know-how, improvements, inventions,
chemical or biological materials, techniques, marketing plans, strategies, customer lists, or other information that has been created, discovered, or developed by a party or its Affiliate, or has otherwise become known to a party or its Affiliate,
or to which rights have been assigned to or by a party or its Affiliate (including, without limitation all information and materials of a party’s (or its Affiliates’) customers and any other third party and their consultants), in each case
that are disclosed by such party or its Affiliate to the other party, regardless of whether any of the foregoing is marked “confidential” or “proprietary” or communicated to the other by the disclosing party in oral, written or
graphic, or electronic form; provided, however, that Confidential Information shall not include any information: 
 (A) that, at the time of its disclosure, is generally available within the industry; 
 (B) that, after its disclosure in connection herewith, becomes generally available within the industry, through no act or failure to act on the part of the receiving party or its Affiliates; 

(C) that becomes available to the recipient of such information from a third party that does not owe a duty of
confidentiality to the disclosing party in relation to that Confidential Information; or 
 (D) that the
recipient of which can demonstrate was independently developed by or for such recipient without the aid, application or use of the Confidential Information disclosed to the recipient by the disclosing party or its Affiliates in connection herewith.

  

			
	CONFIDENTIAL	  	5 | Page

 “Defect” means any flaw making the Product dangerous or unsuitable for use
or otherwise unsuitable for sale. 
 “Deficiency Notice” has the meaning set forth in Section 4.7.

 “Due Delivery Date” has the meaning set forth in Section 4.6. 

“Effective Date” means the date hereof. 
 “EX Works” or :EXW” has the meaning provided in INCOTERM rules of the International Chamber of Commerce of 2010. 
 “FDA” means the United States Food and Drug Administration or any successor government agency. 
 “First Commercial Sale” means the first sale of the Product under this Agreement by Ampio, its Affiliates or Licenses in arms’ length transaction to an unaffiliated Person.

 “Forecast Report” has the meaning set forth in Section 4.1. 

“Ineligible Person” has the meaning set forth in Section 5.6. 

“Infringement Notice” has the meaning set forth in Section 11.1. 

“Intellectual Property” means all (i) patent applications, continuation applications, continuation in part
applications, divisional applications, any corresponding foreign patent applications to any of the foregoing, and any patents that may grant or may have been granted on any of the foregoing, including reissues,
re-examinations and extensions; (ii) rights in know-how, trade secrets, inventions (whether patentable or otherwise), data, processes, techniques, procedures, compositions, devices, methods, formulas,
protocols and information, whether patentable or not; (iii) copyrightable works, copyrights and applications, registrations and renewals; (iv) other intellectual proprietary rights; in each case, whether or not registered, applied for or
granted; and (v) copies and tangible memorializations of any one or more of the foregoing. 
 “Losses” has
the meaning set forth in Section 6.1. 
 “Notice of Observations” has the meaning set forth in
Section 3.6. 
 “Person” means a natural person, corporation, partnership, company or other entity.

 “Pain Field” means the prevention and/or treatment of pain in human beings. 

  

			
	CONFIDENTIAL	  	6 | Page

 “Product” means an oral rapid dissolve or oral disintegrating tablet
formulation of TRAMADOL as the only active pharmaceutical ingredient in [***] dosage strengths for indication outside the Pain Field manufactured in accordance with the Specifications. 

“Quality Agreement” has the meaning set forth in Section 3.9. 

“Regulatory Approval” means the approvals or authorizations of relevant Regulatory Authorities, necessary for the
import, marketing and sale of the Product in the Territory. 
 “Regulatory Authority” means any competent
regulatory authority or other governmental body responsible for approving and authorizing the import, manufacture or marketing of Product in the Territory. 
 “Regulatory Documentation” means all submissions to the FDA or other Regulatory Authorities as applicable, including, without limitation, any clinical data, clinical studies, tests, and
biostudies, NDAs, as well as all correspondence with regulatory authorities, registrations and licenses, regulatory drug lists, advertising and promotion documents, adverse event files, complaint files, manufacturing records and inspection reports,
in each case related to or used in connection with the Product. 
 “Specifications” means all those
manufacturing, testing, packaging, labeling, storage and quality control specifications established for the Product by Ampio in compliance with the requirements of the cGMPs and other regulatory requirements, as set forth in Exhibit C hereto as may
be supplemented or amended from time to time by agreement of the parties, as further defined in the Quality Agreement. 

“Supply Interruption” has the meaning set forth in Section 4.6. 

“Supply Price” has the meaning set forth in Section 4.5 hereof. 

“Technology” means Ethypharm’s proprietary [***] technology, and all patents, patent applications, trademarks,
copyrights, proprietary know-how and all other related Intellectual Property rights owned by Ethypharm relating to the Product. 
 “Term” has the meaning set forth in Section 9.1 hereof. 
 “Territory” means all the different countries where the Product will be marketed by Ampio or its Licenses. 
 “Third Party Manufacturer” has the meaning set forth in Section 2.2. 
  

 

	*	Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities and Exchange Commission.

  

			
	CONFIDENTIAL	  	7 | Page

 ARTICLE 2 

APPOINTMENT OF MANUFACTURER 
 2.1 Requirements. During the Term, subject to Section 4.6 below, Ampio, itself or through its Affiliates or Licensees, shall purchase all of their requirements for Product exclusively from
Ethypharm, or its Third Party Manufacturer as applicable, and Ethypharm, and its Third Party Manufacturer as applicable, shall manufacture and supply to Ampio, its Affiliates and Licenses all of their requirements for Product. All Product
manufactured and supplied hereunder whether by Ethypharm or Third Party Manufacturer shall be performed in compliance with the Quality Agreement and Specifications including cGMP and all applicable laws, rules and regulations. 

2.2 Third Party Manufacturer. Ethypharm shall not subcontract its manufacturing and supply obligations hereunder to any third
party; provided, however, upon the prior written consent of Ampio, Ethypharm shall be entitled to contract with a third party for the purposes of such party’s producing part or all of the Product, and maintaining quality control with
respect to such Product, in lieu of and on behalf of Ethypharm (a “Third Party Manufacturer”) in which case Ethypharm shall remain liable to Ampio for all of its obligations, including but not limited to the performance of the Third
Party Manufacturer, herein, and Ampio shall either (at Ethypharm’s discretion) start purchasing the Product directly from the Third Party Manufacturer (according to the same terms and conditions as apply to the supply of Product by Ethypharm to
Ampio hereunder), or continue purchasing the Product through Ethypharm. Ethypharm shall give Ampio reasonable notice of any proposal to appoint a Third Party Manufacturer and shall satisfy all legal and regulatory requirements relating to any
variation of the Regularity Approval relating to such appointment at its own cost and shall procure for Ampio reasonable inspection and audit rights (which rights are no less favorable to Ampio than those it possesses hereunder with respect to
Ethypharm) in respect of the Third Party Manufacturer’s Manufacturing Site. Ethypharm shall warrant in writing to Ampio that the Third Party Manufacturer: (i) has and will maintain the requisite capacity to satisfy Ethypharm’s
production and delivery obligations, and to meet Ampio’s order requirements, hereunder with respect to the Product in accordance with the Specifications and the terms and conditions of this Agreement; (ii) complies and will comply with all
applicable laws and holds all applicable licensees and permits necessary for the manufacture of the Product in compliance with cGMP; (iii) has and will have the right to use all related intellectual property and Confidential Information of
Ethypharm necessary to manufacture the Product in accordance with the Specifications and the terms and conditions of this Agreement. 
 2.3 Joint Manufacturing Committee. On the Effective Date, the parties will establish a Joint Manufacturing Committee consisting of four members, two of whom shall be appointed by Ethypharm and two
of whom shall be appointed by Ampio. Initially, Ethypharm’s representatives to the Committee shall be Hafid Touam and Antoine Poncy, and Ampio’s representative shall be Amy Poshusta and one additional to be named. The Committee shall meet,
either in person or by teleconference, at least quarterly to discuss the following matters relating to the manufacture and supply of the Product: 
 1. coordinate forecasting, ordering and other supply-related logistics; 

  

			
	CONFIDENTIAL	  	8 | Page

 2. discuss supply-related issues, including shortfalls and quality issues; 

3. discuss and coordinate manufacturing-related complaints, recalls and any other supply related issues; 

4. review and discuss proposals to engage, qualify and maintain Third Party Manufacturers and Additional Manufacturing Facilities; 

5. discuss the content and scope of any quality audit undertaken, or to be undertaken, relating to Third Party Manufacturers; 

6. review and agree on budgets for any additional technical assistance agreed to by the parties; 

7. discuss requirements for supply of Product and mechanisms to maintain supply, e.g., by increasing batch sizes and/or capacity or through
additional sources; 
 8. discuss technology and regulatory issues including tech transfer, changes in Specifications, API sourcing,
stability studies, inspections and audits; and 
 9. perform such other functions as may be appropriate with respect to the manufacture of
the Product. 
 All decisions of the Joint Manufacturing Committee will be made by unanimous vote. If the Committee cannot reach
agreement on any particular issue, the issue will be brought to the Chief Executive Officers of the parties, who shall have a period of 30 days to find an acceptable resolution to the issue. If the issue is not resolved during such 30 day period,
either party may bring the issue to a court of competent jurisdiction for resolution, in accordance with Section 11.1 below. 
 ARTICLE 3 
 REGULATORY AND QUALITY UNDERTAKINGS

 3.1 Regulatory. Ampio, as the holder of the Regulatory Approval, shall be responsible for obtaining,
maintaining and fulfilling all legal and regulatory requirements in the Territory at its own cost, with respect to the Product during the Term, as required by all applicable laws and regulations in the Territory. 

3.2 Import and Packaging. Ampio shall be responsible for the shipping, freight and handling of Product following its delivery to
Ampio at the Commercial Manufacturing Site and shall additionally be responsible for finished product packaging operations with respect to Product and shall ensure compliance with any and all laws and regulations in the Territory to the import and
export of the Product in the Territory. 
 3.3 Change in Specifications. In the event that a Regulatory Authority imposes
any change affecting the manufacture of the Product, the parties, acting through the Joint Manufacturing Committee, shall discuss in good faith with a view to reaching agreement on the 

  

			
	CONFIDENTIAL	  	9 | Page

 
actions and timing required to effect such change, which shall be at the costs and expense of Ampio. All such changes required by any Regulatory Authorities or by Ampio shall be made at
Ampio’s costs and expenses. Any modifications to Specifications and /or the manufacturing instructions shall be implemented and validated in accordance with the terms of the Quality Agreement. 

3.4 Advertising, Promotional Materials, and Public Statements. Ampio shall be solely responsible for all sales, marketing and
advertising activities related to the Product in the Territory and shall ensure that all advertising and promotional materials comply with applicable laws, rules and regulations in the Territory. 

3.5 Product Complaints and Adverse Drug Experiences. Ampio shall, at its sole cost and expense, be responsible for handling all
customer Product complaints and all adverse event reporting, annual reporting, pharmacovigilance and other required, ongoing regulatory reporting activities normally and customarily associated with sales and marketing of pharmaceutical products in
the Territory, in each case, in accordance with applicable laws. 
 3.6 Facility Maintenance; Inspection; Reports. Each
party shall maintain and operate its respective facilities and implement such quality control procedures so as to meet the requirements of applicable FDA or any other relevant regulations and so as to be able to perform timely its obligations
hereunder. Each party shall (and shall cause its Third Party Manufacturers and packagers, if applicable, to) permit quality assurance representatives of the other party to inspect its facilities, including the Commercial Manufacturing Site, once per
calendar year upon reasonable written notice, during normal business hours and on a confidential basis; provided, that, if an inspecting party finds any non-compliance during any such inspection
with respect to the Product, the party subject to inspection shall (i) use Commercially Reasonable Efforts to promptly and diligently rectify such non-compliance and implement appropriate procedures with
a view to avoiding such non-compliance and (ii) permit such additional inspection(s) by the inspecting party as such inspecting party shall deem reasonably necessary to verify that such non-compliance has been rectified. Each party shall promptly provide the other party with a copy of any correspondences exchanged with any Regulatory Authorities, together with the response and corrective action
taken by the party with respect to the Product. 
 3.7 Filing Requirements and Maintenance. Ampio shall promptly comply
with all filing and reporting requirements with respect to the Product, including general reporting requirements necessary to keep and maintain the Regulatory Documentation for the Regulatory Approval current with the Regulatory Authority and any
applicable clinical study. Ampio shall be responsible for conducting all stability studies at its own cost and expense that may be required for ongoing marketing and sale of the Product during the Term and such stability studies shall be conducted
in compliance with the Regulatory Documentation, the Regulatory Approval and other Regulatory Authorities requirements. 

  

			
	CONFIDENTIAL	  	10 | Page

 3.8 Product Recall. 

                (a) Ampio or its
Affiliates, licensees or Licenses shall be responsible for handling the recall or seizure of any Product distributed by or on behalf of Ampio hereunder at its own costs and expense. Notwithstanding the foregoing, in the event Ampio decides to recall
or seize any Product distributed under this Agreement, and such recall or seizure is found to have been caused by a failure of Ethypharm to manufacture the Product in accordance with Specifications or cGMP, Ethypharm shall reimburse Ampio for all
external costs associated with such recall or seizure (including shipping, handling costs and credits to customers). Any decision to recall, withdraw or cease distribution of Product shall be made by Ampio only following consultation with Ethypharm,
taking such reasonable action as it considers to be appropriate under the circumstances to limit the risk to both parties and assure compliance by the parties with the requirements of applicable laws. For purposes of this Section 3.8,
“recall” means (i) any action by Ethypharm, Ampio or any Affiliate of either to recover title to or possession of any Product sold or shipped (including, but not limited to, market withdrawal) and/or (ii) any decision by
Ampio not to sell or ship any Products to third parties that would have been subject to recall if they had been sold or shipped, in each case taken in the good faith belief that such action was appropriate under the circumstances. For purposes of
this Section 3.8, “seizure” means any action by any governmental authority to detain or destroy any Product. 
                 (b) Following the First Commercial Sale, Ethypharm and Ampio shall keep the other fully informed in writing
of any notification or other information, whether received directly or indirectly, that might (i) affect the Regulatory Authority’s approval to market the Product under the Regulatory Approval or the safety or effectiveness of the Product,
(ii) result in liability issues or otherwise necessitate action on the part of either party, or (iii) result in the recall or seizure of the Product. Ampio will be responsible for assuring that such recall is
closed-out with relevant Regulatory Authority. 
 3.9 Quality Agreement. As
promptly as practicable after the Effective Date, but in any event no later than six months following the date of receipt by Ampio or its distributors or licensees of the first Regulatory Approval for the Product in the Territory, the parties will
negotiate in good faith and execute a Quality Agreement (the “Quality Agreement”) setting forth each party’s obligations for ensuring that the Product is manufactured and sold in compliance with cGMP and concerning the delimitation of
pharmaceutical and quality responsibilities for the manufacturing operations of the Product. This agreement shall contain administrative information with responsibilities, supply and manufacturing (premises, materials, batch numbering, shelf life
and other information), customary provisions, including change control, deviation, cGMP compliance, complaint handling and investigation, annual product review, QC testing (specification and method), documentations and inspections, batch release,
product recalls, stability studies and other quality related items in accordance with applicable regulation and guidelines in the Territory. 

  

			
	CONFIDENTIAL	  	11 | Page

 ARTICLE 4 

FORECAST, ORDER, SUPPLY PRICE, SUPPLY INTERRUPTION 
 4.1 Forecast Reports. No later than six months following the date of receipt by Ampio or its distributors or licensees of the first Regulatory Approval for the Product in the Territory, Ampio shall
provide Ethypharm with a twelve (12) month forecast of its estimated requirements of the Product, which shall be updated quarterly during the Term to ensure that Ethypharm has at all times a twelve (12) month forecast for Ampio’s
estimated requirements of the Product (the “Forecast Report”). The Forecast Report shall be expressed in quantities of bulk tablet units of Product. Forecast Reports shall be provided to Ethypharm for information purposes only and
shall not constitute a firm commitment. 
 4.2 Product Orders. Ampio shall provide Ethypharm with binding and non-cancellable orders of the Product four (4) months in advance, except for the first order to support the First Commercial Sale (the “Commercial Launch Supply”) which shall be placed six
(6) months in advance. Ethypharm shall accept all orders by written notice no later than ten (10) days following receipt of each relevant order and shall deliver such quantities of Product ordered unless the quantities ordered by Ampio
vary by more than twenty-five percent (25%) from the quantities indicated in the applicable Forecast Report. Ethypharm shall work with Ampio using Commercially Reasonable Efforts to deliver such quantities of Product that exceed more than
twenty-five percent (25%) of the estimated quantities of Product of the concerned Forecast Report. Ampio shall provide Ethypharm in each order with the exact quantity of Product, delivery date and the address to which the Product must be sent.
These binding orders shall be considered as firm offers and shall bind the Parties as soon as they are accepted in writing by Ethypharm. 
 4.3 Batch Sizes of Product And Inventories.  
 (a) Each binding order placed
by Ampio shall correspond to one full batch or multiple full batches of the Product. A full batch size of Product is defined in Exhibit A of this Agreement. 
 (b) Any proposed change in batch size shall be discussed with the Joint Manufacturing Committee before implementation. Ethypharm shall be responsible for implementing at its own discretion, any change in
batch size during the Term taking into account the Forecast Reports. Ampio shall be responsible for obtaining all regulatory approvals, required, to implement changes in full batch size required hereunder. 

4.4 Inventories. Ampio shall at all times use reasonable efforts to keep adequate inventories of Product to meet the market demand
in the Territory. These inventories shall be sufficient to cover the estimated requirement for at least four (4) months. At Ampio’s request, such inventories shall be kept at Ethypharm’s facility on Ampio’s behalf. 

  

			
	CONFIDENTIAL	  	12 | Page

 4.5 Supply Price of the Product. 

(a) All Product manufactured by Ethypharm or a Third Party Manufacturer, shall be supplied in bulk tablet form ready for
packaging and shall be delivered EX WORKS Ethypharm’s Commercial Manufacturing Site. Ethypharm Supply Price to Ampio is defined in Exhibit B of this Agreement. Ampio or its designated distributor or sublicensee shall be responsible for the
shipping, freight and handling of the Product from Ethypharm’s Commercial Manufacturing Site and finished dosage packaging. Ampio (a) shall pay Product invoices within thirty (30) days of date of invoice. Ethypharm shall supply the
Product in bulk tablet forms ready for packaging and shall deliver the Product to Ampio, EX WORKS (Ethypharm’s Commercial Manufacturing Site) (Incoterm 2010). The Supply Price as determined above includes the active ingredient, excipients,
testing and manufacturing workmanship according to Ethypharm’s usual standards and in compliance with cGMPs. 
 (b) [***] 
 (c) Ampio shall be responsible for all duties, tariffs,
import and similar charges other than sales and use taxes arising out of or related to the manufacture of the Product. None of these costs shall be subject to recoupment by Ampio from Ethypharm under this Agreement. 

(d) At any time during the Term of this Agreement, in the event that one of the Parties produces the written proof that an
unforeseeable event beyond the control of the Parties affects the economical conditions of the present Agreement so as to modify substantially the contractual balance of this Agreement for the sole benefit of one of the Party, the Parties agree to
revise the Supply Prices in good faith, taking into consideration the market of the Product in the Territory, in order to put back both Parties in a situation similar to the existing situation at the date of signature of the Agreement. Each Party
reserves the right to terminate this Agreement if the Parties are unable to reach an agreement within three (3) months starting from the first demand of conciliation by the most diligent Party. 

4.6 Supply Interruption. A “Supply Interruption” shall be deemed to have occurred if Ampio has not received
ordered Product for more than sixty (60) days past the scheduled and agreed upon due delivery date (“Due Delivery Date”) and Ampio holds no saleable stock of the Product after attempting to maintain at least four
(4) months of sealable stock through binding orders made pursuant to Section 4.3 (subject to Ethypharm’s delivery thereof), unless such Supply Interruption is caused by (a) a delay due to a shortage in supply of usable
active pharmaceutical ingredient or any other manufacturing material supplied by a third party through no fault of Ethypharm, (b) a material breach of this Agreement by Ampio for which Ethypharm has provided written notice thereof to Ampio or
(c) a Force Majeure Event. During a Supply Interruption, Ampio, shall be entitled to claim from Ethypharm a penalty of one per cent (1%) of the amount of the late deliveries value of Product from the third week of delay, per each week of
delay. The total amount of penalty to be paid by Ethypharm shall not exceed twenty per cent (20%) of the late deliveries value of Bulk Product not delivered. Such payment shall be made to Ampio within thirty (30) days date of Ampio’s
invoice. Notwithstanding the other provisions of 

  
  

	*	Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities and Exchange Commission.

  

			
	CONFIDENTIAL	  	13 | Page

 
this Agreement, if a Supply Interruption lasts for more than three (3) months, Ampio shall be permitted, at its discretion, (i) to require Ethypharm to use a different supplier for the
Product, once Ampio has provided reasonable notice to Ethypharm of such requirement and/or (ii) to thereafter purchase some or all of its requirement for the Product from a third party of its choosing and Ethypharm shall grant all necessary
licenses and provide all necessary and reasonable cooperation to effect such transfer to the new manufacturing site, on conditions to be agreed in writing by the Parties and subject to appropriate confidentiality agreements being entered into by
such third party. 
 4.7 Deficiency Notice. Ampio shall have the right to reject any portion of any delivery of Product
that deviates from Specifications without invalidating any remainder of such delivery. Ampio shall inspect the Product upon receipt thereof and shall give Ethypharm written notice (a “Deficiency Notice”) of all claims for Product
that deviates from the Specifications within thirty (30) days after Ampio’s receipt thereof (or, in the case of any Defect not reasonably susceptible to discovery upon receipt by Ampio, within thirty (30) days after discovery thereof
by Ampio, up until the final release of the Product in its commercial packaging). Should Ampio fail to provide Ethypharm with a Deficiency Notice within the applicable period, then the delivery shall be deemed to have been accepted by Ampio upon the
expiration of such period. Notwithstanding the foregoing, if Ampio discovers that any Product materially deviates from Specifications after final release of the Product in its commercial packaging, such deviation was not reasonably susceptible to
discovery upon receipt of the Product from Ethypharm, and Ampio reasonably determines that such deviation was due to Ethypharm’s manufacturing, Ampio may reject the delivery of such Product within thirty (30) days after discovery thereof
by Ampio, up until the final expiration date of the Product. 
 4.8 Determination of Deficiency. Upon receipt of a
Deficiency Notice, Ethypharm shall have ten (10) business days to advise Ampio by notice in writing that it disagrees with the contents of such Deficiency Notice. Should Ethypharm fail to provide Ampio with a response to such Deficiency Notice
within the applicable period, then the delivery shall be deemed to have deviated from the Specifications upon the expiration of such period. If Ethypharm responds to such Deficiency Notice during such period and Ampio and Ethypharm fail to agree
within ten (10) business days of the date of Ethypharm’s response to Ampio as to whether any Product identified in the Deficiency Notice deviates from the Specifications, the parties shall mutually select an independent laboratory to
analyze the Product for compliance with the Specifications. Such analysis shall be binding on the parties, and Ampio may reject such Product if such analysis determines that the Product in question deviates from the Specifications. If such analysis
certifies that the Product does not deviate from the Specifications, Ampio shall be deemed to have accepted delivery of such Product on the fortieth (40th) day after delivery (or, in the case of any Defect not reasonably susceptible to
discovery upon receipt of the Product or Defect discovered after final release by Ampio of the Product in its commercial packaging pursuant to Section 4.7 above, on the fortieth (40th) day after discovery by Ampio, but in no event
after the expiration date of the Product). 

  

			
	CONFIDENTIAL	  	14 | Page

 4.9 Rejection for Deficiency. If any delivery of Product is deemed or agreed upon to
deviate from the Specifications, at Ampio’s option, Ethypharm shall either (a) accept a return of such delivery, correct such delivery with replacement Product, if required, as soon as reasonably practicable and reimburse Ampio for its
shipping costs in connection with such delivery and such returns within thirty (30) days, or (b) shall reimburse Ampio for Ampio’s costs (including the purchase price of the Product and shipping costs with respect thereto within
thirty (30) days. 
 ARTICLE 5 
 WARRANTIES AND COVENANTS 
 5.1 Certain Representations and
Warranties of Ethypharm. Ethypharm represents and warrants to Ampio that as of the Effective Date (i) Ethypharm is duly organized and validly existing under the laws of the jurisdiction of its incorporation or organization;
(ii) Ethypharm has the full right, power and authority to enter into this Agreement and to perform the activities required to be performed by it in accordance with this Agreement; (iii) this Agreement is legally binding upon Ethypharm and
enforceable in accordance with its terms, and the execution, delivery and performance of this Agreement by Ethypharm does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be
bound, nor violate any material law or regulation or order of any court, governmental body or administrative or other agency having jurisdiction over it; (iv) there is no action, suit, proceeding or investigation pending or threatened, against
Ethypharm that questions the validity of this Agreement or the right of Ethypharm to enter into this Agreement or consummate the transactions contemplated hereby, nor does Ethypharm have knowledge that there is any basis for the foregoing;
(v) Ethypharm is not in violation of any law or regulation, nor is it aware of any violation of any law or regulation by any other person, which violation could reasonably be expected to adversely affect its performance of its obligations
hereunder and (vi) Ethypharm is the owner or licensee of its Intellectual Property and Technology pertaining to the Product, which is free and clear of any liens, charges and encumbrances. 

5.2 Certain Representations and Warranties of Ampio. Ampio represents and warrants to Ethypharm that as of the Effective Date
(i) Ampio is duly organized and validly existing under the laws of the jurisdiction of its incorporation or organization; (ii) Ampio has the full right, power and authority to enter into this Agreement, to perform the activities required
to be performed by it in accordance with this Agreement; (iii) this Agreement is legally binding upon Ampio and enforceable in accordance with its terms, and the execution, delivery, and performance of this Agreement by Ampio does not conflict
with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction
over it; (iv) there is no action, suit, proceeding or investigation pending or threatened against Ampio that questions the validity of this Agreement or the right of Ampio to enter into this Agreement or consummate the transactions contemplated
hereby, nor does Ampio have knowledge that there is any basis for the foregoing; (v) Ampio is not in violation of any law or regulation, nor is it aware of any violation of any law or regulation by any other person, which violation could
reasonably be expected to adversely affect its performance of its obligations 

  

			
	CONFIDENTIAL	  	15 | Page

 
hereunder; (vi) Prior to First Commercial Sale in any particular jurisdiction, Ampio or its distributor or licensee shall secure the right under the relevant Regulatory Approval to pursue
marketing and sale of the Product in such jurisdiction. 
 5.3 Certain Covenants of Ampio . Ampio covenants and agrees,
on behalf of itself and its Affiliates, that during the Term (i) any Intellectual Property of Ampio, including in particular trademarks of Ampio that are to be utilized by Ampio in connection with the labeling and packaging of the Product are
(or will be) the property of Ampio, may be lawfully used as directed by Ampio; (ii) it will not develop or perform any formulation or any developmental or other work or studies on or with respect to the Product for its own use or benefit or for
the use or benefit of any Person in the Territory, other than pursuant to the development and commercialization of the Product pursuant to the terms of the License Agreement. 
 5.4 Certain Covenants of Ethypharm . Ethypharm covenants and agrees on behalf of itself and its Affiliates and Third Party Manufacturer that it will not during the Term, directly or indirectly
alone, with or through a Third Party, sell, develop, manufacture or market a product containing tramadol anywhere in the world that is a dosage strength that is not a multiple of 25mg or not in the Pain Field, without the prior written consent of
Ampio. 
 5.5 Storage. Tablets of the Product under Ethypharm’s or Ampio’s control (as the case may be) prior
to distribution by Ampio in the Territory shall be stored by Ethypharm or Ampio in a compliant manner and handled in accordance with the Regulatory Documentation and applicable cGMP requirements. 

5.6 Representation and Warranties with Regard to Status . Ampio and Ethypharm each hereby represent and warrant to the other that,
subject to the receipt by Ampio or its distributors or sublicensees of relevant Regulatory Approvals, neither it, their Affiliates, nor in the case of Ethypharm the Third Party Manufacturer nor any of the officers, directors or employees of the
foregoing is prohibited by any law, rule or regulation or by any order, directive or policy from selling the Product or other pharmaceutical products within the Territory and that neither it nor any of its officers, directors, employees or
Affiliates or Third Party Manufacturer is a Person that is listed by a United States federal agency as debarred, suspended or otherwise ineligible for federal programs in the United States, its territories and protectorates (an “Ineligible
Person”) or proposed for such debarment or suspension. 
 5.7 Compliance with Specifications and cGMP .
Ethypharm covenants and agrees that the Product, when delivered to Ampio, will be manufactured, controlled and supplied in accordance with the Specifications and with cGMP; the Product will meet Ethypharm’s quality assurance standards; Product
ingredients and contents will conform with the list and Specifications for ingredients set forth in the Regulatory Approval. Ethypharm will sell the Product to Ampio free of all liens and encumbrances. Ethypharm and Ampio shall execute the Quality
Agreement in accordance with the terms hereof. 

  

			
	CONFIDENTIAL	  	16 | Page

 5.8 Limitation of Warranty. EITHER PARTY GIVES NO OTHER WARRANTY UNDER THIS
AGREEMENT, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF NON-INFRINGEMENT, OF MERCHANTABILITY OR OF FITNESS FOR A PARTICULAR PURPOSE. 
 ARTICLE 6 
 INDEMNIFICATION AND LIMITATION OF LIABILITY

 6.1 Ethypharm’s Indemnification Obligations . Ethypharm shall indemnify and hold Ampio and its Affiliates
and their respective officers, directors, stockholders, employees and agents harmless from and against, and pay or reimburse, any claim, action, suit, proceeding, loss, liability, damage or expense (including reasonable attorneys’ fees)
(collectively, “Losses”) related to claims asserted by any third party, directly or indirectly, as a result of Ethypharm’s or its Affiliates’ or Third Party Manufacturer’s failure to manufacture the Product in
accordance with the Specifications or cGMP or of Ethypharm’s breach of any of its representations, warranties, covenants hereunder; provided, however, that Ethypharm shall not be required to indemnify Ampio with respect to any
such Losses to the extent such Losses arise from or relate to Ampio’s or its Affiliates’ negligent acts or omissions, willful wrongful acts or Ampio’s breach of its representations, warranties, covenants or other obligations
hereunder. 
 6.2 Ampio’s Indemnification Obligations . Ampio shall indemnify and hold Ethypharm and its Affiliates
and their respective officers, directors, stockholders, employees and agents harmless from and against, and pay or reimburse, any Losses related to claims asserted by any third party, directly or indirectly, as a result of: (a) Ampio’s or
its Affiliates’ negligent acts or omissions, willful wrongful acts or breach of any of its representations, warranties, covenants or other obligations hereunder; (b) liabilities, expenses or damages arising from the actions of Ampio to
promote, market, commercialize, distribute and sell the Product in the Territory; and (d) liabilities, expenses or damages arising from the actions of Ampio’s distributors, Affiliates and Licenses or brought by such distributors,
Affiliates or Licenses; provided, however, that Ampio shall not be required to indemnify Ethypharm with respect to any such Losses to the extent such Losses arise from or relate to Ethypharm’s, its Affiliates’ or
subcontractors’ negligent acts or omissions, willful wrongful acts or Ethypharm’s breach of its representations, warranties, covenants or other obligations hereunder. 

6.3 Indemnification Procedures . A party that intends to claim indemnification under this Article 6 (the
“indemnitee”) with respect to any third-party action, claim or liability shall notify the other party (the “indemnitor”) promptly in writing of any action, claim or liability in respect of which the indemnitee
believes it is entitled to claim indemnification; provided, that the failure to give timely notice to the indemnitor shall not release the indemnitor from any liability to the indemnitee except to the extent the indemnitor is
materially prejudiced thereby. The indemnitor shall have the right, by written notice to the indemnitee, to assume the defense of any such action or claim, within the fifteen (15) day period after the indemnitor’s receipt of written notice
of any action or claim, with counsel of the indemnitor’s choice and at the sole cost of the indemnitor. If the indemnitor so assumes such defense, the indemnitee may 

  

			
	CONFIDENTIAL	  	17 | Page

 
participate therein through counsel of its choice, but at the sole cost of the indemnitee; provided, however, if the defendants in any such action include both the party seeking
indemnification and the indemnifying party, and the party seeking indemnification shall reasonably conclude that there may be legal defenses available to it which are different from or additional to, or inconsistent with, those available to the
indemnifying party, the party seeking indemnification shall have the right to select separate counsel to participate in the defense of such action on behalf of such party seeking indemnification, at the indemnifying party’s expense. If the
indemnitor fails to assume such defense and/or to diligently prosecute the same, the indemnitee may assume such defense at the indemnitor’s sole expense. The party not assuming the defense of any such claim shall render all reasonable
assistance to the party assuming such defense, and all reasonable out-of-pocket costs of such assistance shall be for the account of the indemnitor. No such claim shall
be settled other than by the party defending the same, and then only with the prior written consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed; provided, however, that the indemnitee
shall have (i) no obligation to consent to any settlement of any such action or claim that (a) imposes on the indemnitee any monetary or other liability or obligation that is not assumed and agreed to be performed in full by the indemnitor
or (b) adversely affects the indemnitee’s rights hereunder or damages its reputation or business, and (ii) no right to withhold its consent to any settlement of any such action or claim if the settlement involves only the payment of
money by the indemnitor or its insurer without admission of liability by the indemnitee and the indemnitor or its insurer irrevocably agrees in writing to make such payment. If the parties are unable to agree as to the application of Sections
6.1 and 6.2 to any claim, pending resolution of the dispute in accordance with Section 11.1, the parties may conduct separate defenses of such claims, with each party retaining the right to claim indemnification from the other
party in accordance with Sections 6.1 and 6.2 upon resolution of the underlying action. 
 6.4 Limitation of
Liability . NEITHER PARTY SHALL BE LIABLE WITH RESPECT TO ANY CLAIM RELATED TO THIS AGREEMENT FOR ANY SPECIAL, INCIDENTAL OR INDIRECT DAMAGES, INCLUDING ANY LOSS OF INCOME, LOSS OF PROFITS, COSTS OF SUBSTITUTION, COSTS OF COVER OR INCREASED
CAPITAL COSTS, REGARDLESS OF THE FORM OR NATURE OF ACTION, WHETHER IN CONTRACT, BREACH OF WARRANTY, STRICT LIABILITY, EQUITY, INDEMNITY, NEGLIGENCE, INTENTIONAL CONDUCT, TORT OR OTHERWISE, EVEN IF SUCH DAMAGES WERE FORESEEABLE OR IF THE PARTY HAS
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
 ARTICLE 7 

INSURANCE 
 Each of Ampio and Ethypharm shall (and shall cause their respective Affiliates and Sub-licensees, as required, to), upon the Effective Date, carry or be subject to
coverage (as a named insured) under product liability insurance in an amount of not less than [***] combined single limit, which insurance shall be written on a “claims-made” policy basis with an insurance carrier rated at least A- by Bests Rating Service or a comparable rating by a comparable rating service. 

  
  

	*	Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities and Exchange Commission.

  

			
	CONFIDENTIAL	  	18 | Page

 
Each party shall provide the other party with evidence of coverage contemplated hereby, in the form of certificates of insurance, as reasonably requested in writing. Each party shall provide
written notice to the other party fifteen (15) days prior to any material change, cancellation or non-renewal of the policy. 
 ARTICLE 8 
 CONFIDENTIALITY 

8.1 Treatment of Confidential Information . Except as required by applicable laws and regulations or as otherwise provided in this
Article 8, during the Term, and for ten (10) years thereafter, each party shall hold in confidence, and may not disclose, in whole or in part, to a third party (except as specifically set forth herein or with the express prior written
consent of the other party) any and all Confidential Information of the other party and its Affiliates. During the Term, the parties may not use any Confidential Information of the other party and its Affiliates for purposes other than those
permitted by this Agreement and the License Agreement. 
 8.2 Limits on Disclosure . Without limiting the generality of
the foregoing, each party may, with the exercise of reasonable discretion, (i) disclose Confidential Information to those employees or agents who need to receive the Confidential Information in order to further the activities contemplated by
this Agreement; and (ii) make disclosures of such portions of Confidential Information to third-party consultants, attorneys, contractors, advisors, Affiliates and governmental authorities where, in such party’s judgment, such disclosure
is beneficial to the development, approval or marketing of the Product pursuant to this Agreement; provided, that such party shall take reasonable precautions to safeguard the Confidential Information, including by obtaining appropriate commitments
and enforceable confidentiality agreements having provisions no less stringent than those contained herein. 

(a) Each party understands and agrees that the wrongful disclosure of Confidential Information may result in serious and
irreparable damage to the other party, that the remedy at law for any breach of this covenant may be inadequate, and that the party seeking redress hereunder shall be entitled to injunctive relief, without prejudice to any other rights and remedies
to which such party may be entitled. 
 (b) Except as otherwise set forth in this Agreement, upon the termination
or expiration of this Agreement and at the written request of the disclosing party, the receiving party shall return all Confidential Information of the disclosing party (including all copies, excerpts and summaries thereof contained on any media)
or destroy such Confidential Information at the option of the receiving party; provided, that the receiving party may retain one copy of all Confidential Information of the disclosing party for its legal records. 

  

			
	CONFIDENTIAL	  	19 | Page

 ARTICLE 9 

TERM AND TERMINATION 
 9.1 Term. This Agreement shall be effective immediately upon the Effective Date and shall remain into effect for a period of ten (10) years from the Effective Date (the
“Term”). Upon the expiry of the Term, this Agreement will be automatically renewed for one or more additional three (3) year periods, unless terminated by any of the Parties six (6) months prior to the end of the initial
period, or any of the renewed period, by proper notice. 
 9.2 Termination for Breach. If either party commits a material
breach or default in the performance or observance of any of its obligations under this Agreement, other than nonpayment of a monetary obligation, and such breach or default continues for a period of sixty (60) days after delivery by the other
party of written notice reasonably detailing such breach or default, or, if the non-performing party shall promptly, within such sixty (60) days, proceed with all due diligence to cure such failure, and
such failure is not cured within such longer period (not to exceed one hundred eighty (180) additional days) as shall be reasonably necessary for such party to cure the same with all due diligence, then the
non-breaching or non-defaulting party shall have the right to terminate this Agreement, with immediate effect, by giving written notice to the breaching or defaulting
party. Nonpayment of a monetary obligation is deemed a material breach hereunder and the non-breaching party may terminate this Agreement if such breach continues for a period of thirty (30) days after
delivery to the breaching party of written notice of non-payment, with termination effective on the date provided for in that. If either Ethypharm, its Third Party Manufacturer or Ampio becomes an Ineligible
Person, such status shall constitute a material breach hereunder, and the non-breaching party may terminate this Agreement if such breach continues for a period of thirty (30) days after delivery to the
breaching party of written notice of termination, with termination effective on the date provided for in that notice. 
 9.3
Termination for Bankruptcy. To the extent permitted by law, this Agreement shall automatically terminate upon the initiation of any proceeding in bankruptcy, reorganization or arrangement for the appointment of a receiver or trustee to take
possession of the assets of either party or a similar proceeding under law for the release of creditors by or against either party, or if either party makes a general assignment for the benefit of its creditors. 

9.4 Withdrawal of Regulatory Approval and NDA. This Agreement may be terminated with respect to relevant countries in the
Territory by either party in the event that a Regulatory Authority in the Territory withdraws the concerned Regulatory Approval for future marketing of Product in the concerned country of the Territory. 

9.5 No Waiver of Termination Rights. The right of either party to terminate this Agreement, as provided in this Article 9,
shall not be affected in any way by its waiver of, or failure to take action with respect to, any previous default. 

  

			
	CONFIDENTIAL	  	20 | Page

 ARTICLE 10 

FORCE MAJEURE 
 10.1 Effects of Force Majeure. A party hereto shall be excused and shall not be held liable or responsible for failure or delay in fulfilling or performing any of its obligations under this
Agreement (other than the payment of money) if such failure or delay is caused by acts of God, acts of the public enemy, fire, explosion, flood, epidemic or other natural physical disaster, drought, war, terrorists, riot, unavailability of raw
material, sabotage, embargo, strikes or other labor disputes, intervention of governmental authority, impossibility of the use of railways, shipping, aircraft, motor transport or other means of public or private transport, failure or suspension of
utilities, and political interference with the normal operation of either party or by any other event or circumstance of like or different character to the foregoing beyond the reasonable control and without the fault or negligence of the affected
party (a “Force Majeure Event”). Such excuse shall continue as long as the Force Majeure Event continues. Upon cessation of such Force Majeure Event, such party shall promptly resume performance hereunder. 

10.2 Notice of Force Majeure. Each party agrees to give the other party prompt written notice of the occurrence of any Force
Majeure Event, the nature thereof and the extent to which the affected party will be unable to perform its obligations hereunder. Each party further agrees to use reasonable efforts to correct or otherwise address the Force Majeure Event as soon as
practicable and to give the other parties prompt written notice when it is again fully able to perform such obligations. 

ARTICLE 11 
 Miscellaneous 
 11.1 Dispute Resolution. Ethypharm and Ampio
agree to irrevocably submit to the exclusive jurisdiction of (i) the Supreme Court of the State of New York, New York County, U.S.A., or (ii) the United States District Court for the Southern District of New York U.S.A., for the purposes
of any suit, action or other proceeding arising out of this Agreement or any transaction contemplated hereby. Each Party agrees to commence any such action, suit or proceeding either in the United States District Court for the Southern District of
New York, U.S.A. or, if such suit, action or other proceeding may not be brought in such court for jurisdictional reasons, in the Supreme Court of the State of New York, New York County, U.S.A. 

EACH PARTY HERETO WAIVES, TO THE EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT TO ANY LITIGATION DIRECTLY OR
INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT, AND EACH PARTY HERETO (i) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN
THE EVENT OF LITIGATION, SEEK TO ENFORCE THAT FOREGOING WAIVER, AND (ii) ACKNOWLEDGES THAT IT AND THE OTHER PARTY HERETO HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS
PARAGRAPH. 

  

			
	CONFIDENTIAL	  	21 | Page

 11.2. Independent Contractors. The relationship between Ethypharm, on the one hand,
and Ampio, on the other hand, is that of independent contractors and nothing herein shall be deemed to constitute or create the relationship of partners, joint venturers nor of principal and agent between Ethypharm on the one hand and Ampio on the
other hand. Neither party shall have any express or implied right or authority to assume or create any obligations on behalf of or in the name of the other party or to bind the other party to any contract, agreement or undertaking with any third
party. 
 11.3. Assignment. This Agreement may be assigned and/or delegated by either party to an Affiliate of such party
or in connection with any sale, merger or other business combination involving all or substantially all of such party’s assets or capital stock or of the assets to which this Agreement relates. Except as otherwise provided in this Agreement,
neither this Agreement nor any other rights or obligations hereunder shall be assigned, transferred or delegated by either party without the prior written consent of the other party, not to be unreasonably withheld, conditioned or delayed. Any
permitted assignee shall, upon the request of the other party hereto, expressly acknowledge, by written agreement, its assumption of all obligations and liabilities under this Agreement. Any attempted assignment in violation of the foregoing shall
be null and void. This Agreement shall inure to the benefit of each party’s permitted successors and assigns. 
 11.4.
Governing Law. This contract shall be governed by, and construed in accordance with, the laws of the State of New York without reference to that state’s conflicts of laws rules. The parties expressly reject the application of the United
Nations Convention on Contracts for the International Sale of Goods and all implementing legislation thereunder. 
 11.5. No
Implied Waiver. No failure or delay on the part of either party hereto to exercise any right, power or privilege hereunder or under any instrument executed pursuant hereto shall, in itself, operate as a waiver; nor shall any single or partial
exercise of any right, power or privilege preclude any other or further exercise thereof or the exercise of any other right, power or privilege. 
 11.6. Notice. All notices required to be given hereunder shall be in writing and shall be given by personal delivery, via facsimile transmission followed by U.S. mail, by a nationally recognized
overnight carrier or by registered or certified mail, postage prepaid with return receipt requested. Notices shall be addressed to the parties as follows: 
 If to Ethypharm: 
 Ethypharm S.A. 

194 Bureaux de la Colline 
 F92213 Saint-Cloud 

  

			
	CONFIDENTIAL	  	22 | Page

 France 
 Attn: Hugues LECAT—Chairman of the Board—CEO 
 Facsimile No.: +33 1 41 12
17 30 
 With a copy (which shall not constitute notice) to: 

Ethypharm USA Corp. 
 1500 Market Street, 12th Floor, East Tower 
 Philadelphia, PA 19102 

Attn: Hafid Touam-CEO 
 Facsimile No.: (610) 994-2302 
 If to
Ampio: 
 Ampio Pharmaceuticals, Inc. 
 The Quadrant 
 5445 DTC Parkway, Suite 925 

Greenwood Village, CO 80111 
 U.S.A. 
 Attn: Michael Macaluso—Chairman of the Board and CEO 

Facsimile (720) 437-6501 

With a copy (which shall not constitute notice) to: 
 Goodwin Procter LLP 
 Exchange Place 

Boston, MA 02109 

Attention: Larry Wittenberg 
 Facsimile: 617-523-1231 
 Notices delivered personally shall be deemed communicated as of actual receipt; notices sent via facsimile transmission shall be deemed communicated as of receipt by the sender of written confirmation of
transmission thereof; notices sent via overnight courier shall be deemed received as of one business day following sending; and notices mailed shall be deemed communicated as of three (3) business days after proper mailing. A party may change
his or its address by written notice sent in accordance with this Section 12.6. 
 11.7. Amendments. Any
amendment or modification of this Agreement shall be valid only if made in writing and signed by both parties hereto. 
 11.8.
Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original and both of which shall constitute a single document. A facsimile signature of an authorized signatory of either party shall be valid and
binding and constitute due execution and delivery of this Agreement by such party. 

  

			
	CONFIDENTIAL	  	23 | Page

 11.9. Interpretation. The Section headings contained in this Agreement are for the
convenience of reference only and shall not affect the meaning or interpretation of this Agreement. As used in this Agreement, any reference to the masculine, feminine or neuter gender shall include all genders, the plural shall include the
singular, and the singular shall include the plural. Unless the context otherwise requires, the term “party” when used herein means a party hereto. References herein to a party or other Person include its respective successors and
permitted assigns. The words “includes” and “including” when used herein shall be deemed to be followed by the phrase “without limitation” unless such phrase otherwise appears. Unless the context
otherwise requires, references herein to Articles, Sections, Exhibits and Schedules shall be deemed references to Articles and Sections of, and Exhibits and Schedules to, this Agreement. Unless the context otherwise requires, the words
“hereof,” “hereby,” “hereunder” and “herein” and words of similar meaning when used in this Agreement refer to this Agreement in its entirety and not to any particular Section or
provision hereof. All monetary amounts in this Agreement are expressed and shall be paid in U.S. dollars. With regard to each and every term and condition of this Agreement, the parties understand and agree that the same has or have been mutually
negotiated, prepared and drafted, and that, if, at any time, the parties desire or are required to interpret or construe any such term or condition or any agreement or instrument subject thereto, no consideration shall be given to the issue of which
party actually prepared, drafted or requested any term or condition of this Agreement. 
 11.10. Entire Agreement. This
Agreement and the License Agreement constitutes the entire understanding between the parties with respect to the subject matter hereof and supersedes all prior contracts, agreements and understandings related to the same subject matter between the
parties. In particular, in case of inconstancies between the terms of the License Agreement and the terms of this Agreement with respect to the manufacture and supply of the Product, the terms of this Agreement shall prevail. The parties intend this
Agreement to be a complete statement of the terms of their understanding. 
 11.11. Benefit; Binding Effect. This
Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns. 
 11.12. Survival. Notwithstanding anything to the contrary contained in this Agreement, the provisions of Article 3 (to the extent of post-termination complaints and reporting obligations)
and Articles 1, 5, 6, 7, 8 11and 12 shall survive, in accordance with their respective terms, any termination or expiration of this Agreement. 

11.13. Further Assurances. The parties agree that they shall take all appropriate actions, including the execution or filing of
any documents or instruments, that may be reasonably necessary or advisable to carry out the intent and accomplish the purposes of any of the provisions hereof. 
 11.14. Severability. In the event that any provision of this Agreement shall be held invalid or unenforceable for any reason by a court of competent jurisdiction, such provision or part thereof
shall be considered separate from the remaining provisions of this Agreement, which shall remain in full force and effect. Such invalid or unenforceable provision shall be deemed revised to effect, to the fullest extent permitted by applicable law,
the intent of the parties as set forth herein. 

  

			
	CONFIDENTIAL	  	24 | Page

 11.15. Use of Names; Publicity. Neither party will use the name of the other party or
issue any press release or other publicity relating to this Agreement in any form without the written permission of the other, except as may be required by applicable law (including securities exchange rules) or as otherwise contemplated hereunder.
Neither party will unreasonably withhold its written permission if the other party desires to issue such a press release or other publicity with respect to this Agreement. 

  

			
	CONFIDENTIAL	  	25 | Page

 IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the
Effective Date. 
 Date: 
  

			
	ETHYPHARM S.A.
		
	By:	 	/s/ Hugues LECAT
	Name:	 	Hugues LECAT
	Title:	 	CEO—Chairman of Management Board

  

			
	AMPIO PHARMACEUTICALS, INC.
		
	By:	 	/s/ Michael Macaluso
	Name:	 	Michael Macaluso
	Title:	 	Chairman of the Board and CEO

  

			
	CONFIDENTIAL	  	26 | Page

 EXHIBIT A 
 BATCH SIZE DEFINITION 
 A full batch size of Product represents [***]. 

 
  

	*	Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities and Exchange Commission.

  

			
	CONFIDENTIAL	  	27 | Page

 EXHIBIT B 
 SUPPLY PRICES 
 Ethypharm Supply prices of Product expressed EX WORKS (Ethypharm Commercial
Manufacturing Site) taxes excluded, in bulk tablets, to Ampio shall be: 
 [***] 
 [***] 
 The Supply Price as determined above includes the supply of excipients and active
drug, the analysis of active drug and excipient, the manufacturing operations according to the standards of ETHYPHARM and the delivery in bulk packaging Ex Works as indicated. 

 
  

	*	Confidential Information indicated by [***] has been omitted from this filing and filed separately with the Securities and Exchange Commission.

  

			
	CONFIDENTIAL	  	28 | Page

 EXHIBIT C 
 PRODUCT SPECIFICATIONS 

  

			
	CONFIDENTIAL	  	29 | Page

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]